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CHAPTER I 
 
INTRODUCTION 
 
STRAP is a 39 kDa protein of WD-40 family involved in probable scaffolding 
function during the formation of multiprotein complexes, first shown to be active in the 
Transforming growth factor-β (TGF-β) receptor signaling network. Oncogenic STRAP is 
up-regulated in human cancers and may be involved in tumor progression. 
 
Characteristics 
 STRAP was first cloned from mouse embryonic cDNA library while searching 
for novel proteins that bind the cytoplasmic region of TGF-ß type I receptor (TβRI) using 
the yeast two-hybrid screening (Datta el al., 1998).  Later it was found that STRAP could 
associate with both type I and Type II (TßRII) serine-threonine kinase receptors (Datta et 
al., 2000).  Southern blot analyses demonstrate that STRAP is evolutionarily conserved 
from yeast to mammals.  The importance of this conservation was revealed when STRAP 
knockout mice were generated using the gene-trap mutagenesis technology coupled with 
microarray in the process of identifying probable targets of platelet-derived growth factor 
(PDGF) signaling (Chen et al., 2004).  STRAP was found to be a PDGF-BB-inducible 
gene.  The gene trap insertion results in embryonic lethality between embryonic day (E) 
10.5 and E12.5.  Later STRAP was also identified in humans as an interacting protein 
with upstream of N-ras (unr) that is involved in the internal initiation of translation of 
 2 
human rhinovirus RNA and is implicated in cap-independent translation (Hunt et al., 
1999). 
 
The human STRAP gene is located in chromosome 12p12.3 near the marker 
D12S1593 (Matsuda et al., 2000).  Northern blot analysis, using different tissues in mice, 
indicated a major transcript of 1.8 kb, though in some tissues a larger transcript was 
detectable.  This may suggest alternative splicing of the STRAP RNA at least in some 
tissues.  It is ubiquitously expressed in all mouse tissues with highest levels in liver and 
testis and less abundantly in spleen.  In humans, STRAP expression has also been shown 
to be ubiquitous and it forms a 2 kb transcript.  Both human and mouse STRAP gene 
contains 10 exons which finally forms a 350 amino acid protein migrating with an 
apparent mass of 39 kD on SDS-PAGE.  Murine STRAP has more than 97% amino acid 
identity over the entire sequence with its human version.  Sequence analysis indicates that 
STRAP contains seven WD40 repeats.  STRAP shows a 55 % similarity in base pairs and 
a 19 % similarity in amino acid sequence to another known WD40 protein TRIP-1. Some 
of these similarities are among the conserved amino acid residues within the WD repeats.  
STRAP is localized predominantly in the cytoplasm but a good level is also present in the 
nucleus.  It forms homo-oligomers probably through the WD repeats and this may be 
important for the multi-protein complex assembly.  The physical interaction of STRAP 
with the TGF-ß receptor complex raises the possibility that STRAP is a substrate of the 
receptors.  Our findings showed that an increase in the phosphorylation of STRAP 
requires the kinase activity of receptors in vivo, but STRAP does not appear to be a direct 
 3 
substrate of the receptors during in vitro kinase assays.  The C-terminal 57 amino acids 
are important for this phosphorylation. 
 
 
Figure 1. Structural considerations for STRAP (A) STRAP has 7 WD-40 repeats in 
the N-terminal region and a low complexity short C-terminal chain that is known to be 
phosphorylated. (B) WD-40 domains together form a β-propeller structure. Here is a 
sample structure of the yeast Cdc4 protein having 8 WD40 repeats forming an eight-
bladed β-propeller structure. (Adopted from Orlicky S. et al. (2003) Cell. 112(2): 243-
256) 
 
As stated earlier, STRAP belongs to the family of WD repeat proteins that are 
known to have four or more repeating units containing a conserved core of approximately 
 WD-domain (GH-
WD) 
       
35
1 
29
4 
1 
 
 
A 
B 
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40 amino acids that mostly end with tryptophan-aspartic acid (WD).  Most of them are 
thought to form a circularized β propeller structure.  Though the underlying common 
function is coordinating multiprotein complex assemblies, these proteins are also 
involved in various cellular processes like signal transduction, transcriptional regulation, 
programmed cell death, RNA synthesis/processing, chromatin assembly, cell cycle 
progression and vesicular trafficking.  Other common examples of WD repeat proteins 
are the β subunit of the G proteins, TATA box binding protein associated factor II 
(TAFII), apoptotic protease-activating factor 1 (APAF-1), retinoblastoma-binding protein 
p48 (RbAp-48), receptor of activated protein kinase C 1 (RACK1), phospholipase A2-
activating protein (PLAP) or TGF-beta receptor-interacting protein 1 (TRIP-1), which is 
also known to interact with TβRII (Chen et al., 1995). Structural analysis of the WD 
repeat proteins in general shows that they act as a very rigid platform or scaffold 
irrespective of the proteins they interact with.  
 
This is evident from the fact that apart from TβRI and TβRII (Datta et al., 1998), STRAP 
also binds with Smad2, Smad3, Smad6, Smad7, 3-phosphoinositide-dependent protein 
kinase 1 (PDK1) (Seong et al ., 2005), Ewing‟s sarcoma protein (EWS) ( anumanthan et 
al., 2006), hMAWD binding protein (MAWBP) (Matsuda et al., 2000), unr (Hunt et al., 
1999), microtubule associated protein 1B (MAP1B) (Iriyama et al., 2001), nuclear export 
factor (NXF) proteins (Tretyakova et al., 2005), Gemin6, Gemin7, and 3 small nuclear 
ribonucleoproteins  (SmB), SmD2, SmD3 (Meister et al., 2001 and Carissimi et al., 
2006), ASK1 (Jung et al., 2010), NM23-H1 (Jung et al ., 2007) and also GSK3β and 
Notch3 as found in our current study.  Figure 1B shows an example of the yeast WD40-
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repeat protein Cdc4 with the substrate being able to interact with the WD40-repeates only 
after appropriate phosphorylation. 
 
STRAP in TGF-β Signaling Pathway 
TGF-beta binds with the TGF-β receptor to induce a hetero-dimeric complex of 
TBR-I and TBR-II and signals though both Smad-dependent and the Smad-independent 
pathways (Derynck et al., 2003; Bierie et al., 2006 and Feng et al., 2005). TGF-β 
signaling is known to regulate diverse biological functions such as growth, 
differentiation, EMT, invasion, and apoptosis (Zavadil et al., 2005; Schuster and 
Kriglstein, 2002).  As far as cancer progression is concerned, Smad-dependent pathway 
seems to suppress tumor formation by inhibiting cell cycle progression and inducing 
apoptosis.  TBRI phosphorylates receptor associated Smads (R-Smads) -2 and -3 that 
binds to the common Smad-4 and translocate to the nucleus.  This complex can activate 
or suppress transcription from TGF-beta target genes depending on the type of 
transcriptional regulators it associates with.  
 
In the Smad-independent pathway, TGF-β can activate MAP kinase signaling 
pathway, TGF-beta activated kinase 1 (TAK1) (Kimura et al., 2000), p38 (Morigouchi et 
al., 1996), JNK (Shirakabe et al., 1997; Engel et al., 1999), RhoA (Bhowmick et al., 
2001), Ras and phosphoinositide 3-kinase (PI3K) pathways (Bakin et al. 2000; Chen et 
al. 1998).  In contrast to the Smad pathway, the Smad-independent pathways are believed 
to play a role in the pro-oncogenic functions of TGF-β (Wakefield and Roberts 2002). 
Smad-independent pathways have been reported to promote cell survival, EMT, and 
migration; and several independent studies suggest that these pathways can induce 
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malignant characteristics to normal and neoplastic cells (Massague 2008). Whether a 
Smad-dependent or Smad-independent pathways will prevail in a certain cell depends on 
the specific cell type and still very unclear. Our recent report does indicate that 
mechanisms like loss of Smad4 expression can be one such event that can favor the 
Smad-independent pathways ahead of Smad-dependent pathway (Zhang et al., 2010).  
 
STRAP binds with both TβRI and TβRII in a ligand independent manner.  It 
synergizes specifically with Smad7, but not with another inhibitor Smad6, in the 
inhibition of TGF-ß signaling (Datta et al., 2000).  STRAP stabilizes the association 
between Smad7 and activated receptor complex, thus assisting Smad7 in preventing 
phsophorylation and activation of Smad2 and Smad3 by the receptor complex.  Though 
Smad6 is also shown to interact with STRAP, this association does not seem to interfere 
with bone morphogenic protein (BMP) signaling in which Smad6 acts as an inhibitor.  
STRAP inhibits TGF-ß-induced nuclear translocation of Smad2/3 and Smad4 and as a 
result, activation of TGF-ß responsive reporter genes including plasminogen activator 
inhibitor 1 (PAI-1) and p21Cip1 is abrogated.  Downregulation of p21Cip1 by STRAP 
leads to hyperphosphorylation of retinoblastoma protein (pRb).  In vitro kinase assay 
demonstrated that overexpression of STRAP can induce extracellular signal-regulated 
kinase (MEK/ERK) activity in a TGF-ß-independent manner.  Activation of MEK/ERK 
pathway by endogenous STRAP was further confirmed by knocking STRAP down using 
small interfering RNA (siRNA) (Halder et al., 2006).  Although STRAP is not a kinase, it 
may facilitate the activation of MAPK pathway through functioning as a scaffold for 
upstream kinases.  Therefore, STRAP may inhibit activation and nuclear translocation of 
Smad2 and Smad3 by interacting with receptors and Smad7 and/or by activating 
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MAPK/ERK pathway. Additional unpublished data from our lab now indicates that 
STRAP may mediate activation of other Smad-independent pathways. Further work will 
be needed to confirm these findings and understand the exact role of STRAP in activating 
these pathways. 
 
Role of STRAP in PDK1-mediated Signaling 
 3-phosphoinositide-dependent protein kinase-1 (PDK1) has been shown to 
phosphorylate and activate many members of the protein kinase A, G, and C subfamily 
that include protein kinase B (PKB), p70 S6 ribosomal kinase, p21-activated kinase 1 
(PAK1) and serum/glucocorticoid regulated kinase (SGK) (Mora et al., 2004).  PDK1 
signaling is implicated in cellular proliferation, survival, migration, and invasion of tumor 
cells. STRAP interacts with the catalytic domain of PDK1 and modulates PDK1 activity.  
Seong et al. (2005) showed that STRAP promotes phosphorylation of PDK1 substrates 
S6K, Akt, and Bad. This interaction of STRAP and PDK1 is inhibited by TGF-β and 
induced by insulin.  The induction in binding by insulin is abrogated by wortmannin, a 
PI3K inhibitor.  The mechanism behind PDK1 activation by STRAP is thought to be 
displacement of the 14-3-3 protein from PDK1 complex, which negatively regulates it 
(Fig. 2).  The binding of PDK1 with STRAP also potentiates negative regulation of TGF-
β mediated transcription by STRAP.  This repression occurs through increased 
association of Smad7 with both STRAP and TβRI.  Finally, interaction between STRAP 
and PDK1 induces cell survival probably through phosphorylation of Bad and attenuation 
of tumor necrosis factor-alpha (TNF-α) induced apoptosis. 
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STRAP interacts with NM23-H1 
NM23-H1 is currently thought of as a putative metastasis suppressor because of 
its reduced expression in a few highly metastatic cell lines and tumors. There are eight 
NM23 genes in humans namely NM23-H1, NM23-H2, NM23-H3, NM23-H4, NM23-
H5, NM23-H6, NM23-H7, and NM23-H8 that encode for DNA-binding nucleoside 
diphosphate kinases (Lacombe et al., 2000). Multiple studies have shown that these 
kinases affect a broad spectrum of cellular responses, including development, 
differentiation, proliferation, endocytosis, and apoptosis (Steeg et al., 2008; Fan et al., 
2003). The molecular mechanisms underlying the role of NM23-H1 as a metastasis 
suppressor, however, have so far remained unclear.  
There have been contrasting reports about the effect of NM23 on TGFβ signaling. 
Earlier studies indicate a potentiating role for NM23-H1 during Smad-dependent 
signaling in HT29 colon cancer cells but a later report indicates that NM23-H1 can 
associate with STRAP to reduce transactivation of Smad-dependent reporter genes (Hsu 
et al., 1994; Seong et al., 2007).  A more recent study shows that NM23-H1 and STRAP 
interact with p53 and potentiate p53 activity (Jung et al., 2007). Both NM23-H1 and 
STRAP were shown to directly interact with the central DNA binding domain of p53 and 
remove Mdm2 from the p53-Mdm2 complex. Mdm2 is a known negative regulator of 
p53.  The knowledge about the exact role of STRAP-NM23-H1 complex formation in 
p53 signaling is still in early phase and warrants further investigation. 
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Figure 2. Role of STRAP as a scaffold in diverse signaling pathways. Please see the 
text for detailed discussion. 
 
 
STRAP in ASK1-dependent signaling 
ASK1 (apoptosis signal-regulating kinase 1) is a mitogen-activated protein kinase 
kinase kinase (MAPKKK) that phosphorylates mitogen-activated protein kinase kinases 
MKK3, -4, -6 and -7 and in turn activate the c-Jun N-terminal kinase (JNK)3/p38 
signaling cascade (Chen et al., 1999). A diverse range of factors including stress-related 
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stimuli, tumor necrosis factor-α, Fas ligand, endoplasmic reticulum stress and calcium 
excess can stimulate ASK1 activity and thioredoxin (Trx), glutaredoxin, glutathione S-
transferase μ (GSTμ), heat shock protein 72, 14-3-3 etc. can inhibit ASK1 activity 
(Matsukawa et al., 2004).  This regulation has been proposed to be achieved through 
protein-protein interactions. Consistent with this, ASK1 was shown to interact with 
STRAP through the C-terminal region of ASK1. Functionally, STRAP inhibited ASK1-
mediated signaling to both JNK and p38 kinases (Jung et al., 2010). STRAP has a 
stabilizing effect on a complex between ASK1 and thioredoxin and 14-3-3 that are 
known negative regulators of ASK1. This prevents complex formation between ASK1 
and its downstream substrate MKK3 thus effectively inhibiting ASK1 signaling. 
Functionally, this effect on ASK1 activity resulted in STRAP inhibiting H2O2-mediated 
apoptosis in a dose-dependent manner. This is in direct contrast to the role of STRAP in 
PDK1 signaling where STRAP has an activating effect on PDK1 by displacing protein 
14-3-3 and thus enabling PDK1 to phosphorylate its downstream substrates. This 
suggests that role of STRAP can be dependent on the specific protein it associates with 
and not dependent on a certain fixed mechanism. Additionally, ASK1 phosphorylates 
STRAP at Thr175 and Ser179 within a region between the WD4 and WD5 domains that 
subsequently leads to ASK1 activity inhibition though the exact mechanism of this is not 
well understood. 
 
Role of STRAP in the SMN complex and cap-independent translation 
 
The survival of motor neurons (SMN) gene is considered to be responsible for the 
neurodegenerative disorder spinal muscular atrophy (SMA) (Battaglia et al., 1997). In 
 11 
cells, SMN is part of a stable multiprotein complex in the cytoplasm and in nuclei. Apart 
from the SMN protein itself, the SMN complex contains six other proteins, called 
Gemins2–7. The SMN complex plays a vital role in the assembly of the spliceosomal 
Uridine-rich small nuclear ribonucleoproteins (U snRNPs).  STRAP seems to be involved 
in this assembly through its interaction with STRAP with Gemin6 and Gemin7 as well as 
SmB, SmD2 and SmD3 components of SMN complex (Grimmler et al., 2005; Carissimi 
et al., 2005). Interestingly, Gemin5 which is one of the SMN complex components 
STRAP does not interact with, is also a WD40-repeat protein. Although STRAP is 
localized in both cytoplasm and nucleus, it is present predominantly in the cytoplasm and 
may help the nuclear-cytoplasmic distribution of the SMN complex.  The presence of 
STRAP in the SMN complexes was shown to be essential for U snRNP assembly as 
depletion of STRAP using a specific antibody markedly reduces snRNP assembly 
(Carissimi et al., 2005). In contrast, STRAP was also shown not to be essential for this 
assembly by another report from Grimmler et al. (2005). Thus presently, there is no 
conclusive understanding of the role of STRAP in this macromolecular SMN complex.  
 
unr is a cytoplasmic RNA binding protein that plays an important role in the 
initiation of HRV-IRES dependent (cap-independent) translation of the animal 
picornavirus RNA like the rhinoviral RNA.  STRAP interacts with unr and was named 
unr-interacting protein (unrip) for this role. It was found that STRAP did not appear to 
play any role in the initiation of viral translation.  But STRAP could increase c-myc 
internal ribosomal entry site (IRES) activity though again the significance of STRAP in 
this process is not well understood.   
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Miscellaneous functions of STRAP 
 Ewing‟s sarcoma is a rare malignant round-cell tumor found in the bone or in soft 
tissue. Though fusion product of EWS gene and ETS family gene has been implicated in 
Ewing‟s Sarcoma, little is know about the wild type EWS protein (Uren et al., 2005). 
STRAP is localized in both cytoplasm and nucleus.  It colocalizes and associates with the 
oncogenic EWS protein in nucleus through its NH2 and COOH termini (Anumanthan et 
al., 2006).  STRAP inhibits the interaction between EWS with p300, a protein that is a 
transcriptional co-activator of EWS.  This results in downregulation of EWS target genes 
like ApoCIII and c-fos.  Although TGF-β has no effect on the interaction between 
STRAP and EWS, TGF-β-dependent transcription is inhibited by EWS. 
 
 In an interesting finding, STRAP along with EWS was shown to be present in the 
kinesin driven mRNA transport granules in the dendrites of murine neurons (Tretyakova 
et al., 2005).  In eukaryotes, the nuclear export of mRNA is mediated by nuclear export 
factor 1 (NXF1) receptors.  As shown in mouse neuroblastoma N2a cells, NXF proteins 
bind to brain-specific microtubule associated proteins (MAP) such as MAP1B and also 
STRAP.  Additionally, MAP1B also binds with STRAP.  This assembly helps in nuclear 
export of mRNA.  In an independent setting, NXF-7 binds with MAP1B and STRAP 
only in the cytoplasm and colocalizes with Staufen1 containing mRNA transport granules 
in the neurites of these cells (Fig. 2) (Kanai et al., 2004).  As in other cases, STRAP 
seems to play a role in the multiprotein complex assembly required for both nuclear 
export of mRNA and the cytoplasmic transport of mRNA containing granules along 
microtubules. 
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 Recently, it was shown that STRAP is a substrate for SUMO4 (a novel member of 
the SUMO gene family) sumoylation.  Although the significance of this is not yet known, 
SUMO4 sumoylation is predicted to have a role in the regulation of intracellular stress.  It 
will be interesting to determine whether sumoylation of STRAP has any effect on its 
biological functions. 
 
 
Figure 3. STRAP in development. Gross morphology of wild-type (left) STRAP -/- 
(right) embryos at E9.5 and E10.5. Mutants had underdeveloped yolk sac vasculature, 
arrested neural tube closure and embryonic turning, as well as abnormal hearts and 
somites. (From W. Chen, J. Delrow, P. Corrin, J. Frazier, P. Soriano, Nat. Genet. 2004, 
36; 304–312) 
 
 
STRAP in development 
Chen et al. (2004) identified STRAP as a PDGF-BB-inducible gene in a pilot 
gene-trap array screen. The gene-trap insertion resulted in a null allele and recessive 
E9.5 E10.5
Wild Type STRAP -/- Wild Type STRAP -/-
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embryonic lethality between embryonic day (E) 10.5 and E12.5. Homozygous mutant 
embryos had defects in angiogenesis, cardiogenesis, somitogenesis, neural tube closure 
and embryonic turning (Figure 3). Coupled with conservation of STRAP from yeast to 
humans, this highlights an indispensable function for STRAP during early development.  
Recently, drosophila STRAP homologue, pterodactyl, has been implicated in 
tubulogenesis and branching morphogenesis defects (Khokhar et al., 2008). 
 
Clinical aspects 
 Although STRAP seems to be involved in mutually independent biological 
functions, there is increasing clinical and experimental evidence suggesting that STRAP 
acts as an oncogene.  The level of STRAP is found to be altered in different cancers.  The 
protein level is elevated in 60% of colorectal, 78% of lung and 46 % of the breast 
carcinomas (Halder et al., 2006; Matsuda et al., 2000 and Kim et al., 2007).  Several lines 
of evidence suggest that carcinoma cells frequently lose the tumor suppressor function of 
TGF-β (Bierie et al., 2006).  Upregulation of TGF-β signaling inhibitors like STRAP and 
Smad7 and their synergistic function presents a novel intracellular mechanism by which a 
portion of human tumors become refractory to antitumor effects of TGF-β.  STRAP also 
exerts several other biological functions in a TGF-β independent manner that contributes 
to cell proliferation and inhibition of apoptosis. 
 
 Ectopic expression of STRAP in different cell lines promotes cellular 
proliferation, induces anchorage-independent growth and increases tumorigenicity during 
in vitro and in vivo experiments (Halder et al., 2006).  Downregulation of p21
Cip1
 that 
results in hyperphosphorylation of pRb as well as activation of MAPK/ERK pathway 
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may contribute to tumorigenic effects of STRAP during tumor formation and 
progression.  As noted earlier, STRAP also has an anti-apoptotic role probably through 
Bad phosphorylation and inhibition of TNF-α induced apoptosis (Seong et al., 2005).  It 
has been recently shown that STRAP interacts with Ewing Sarcoma protein (EWS), an 
oncoprotein known to be involved in 80% of Ewing tumors after chromosomal 
translocations (Anumanthan et al., 2006).  Normal EWS protein is also upregulated in 
human cancers, which correlates with the upregulation of STRAP in 71% of colorectal 
cancers and 54% of lung cancers, suggesting a cooperative role of these two proteins in 
human cancers.  In an attempt to determine whether STRAP is of prognostic value or 
predictive of chemotherapy benefit, STRAP gene was found to be amplified in 23% of 
colorectal tumors and amplification of STRAP in patients without adjuvant chemotherapy 
was found to exhibit better prognosis (Buess et al., 2004).  Interestingly, these patients 
had a worse survival when treated with adjuvant therapy when compared with patients 
without chemotherapy.  In contrast, patients carrying tumors with diploidy or deletion of 
STRAP benefited from the treatment.  These results suggest that STRAP is an 
unfavorable prognostic marker for 5-FU-based adjuvant chemotherapy. Taken together, 
STRAP appears to facilitate multiple steps in the process of tumorigenesis and possibly 
during metastasis, and it could be a potentially important drug target for therapeutic 
intervention in human cancers. 
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Aims of Dissertation 
The aims of this dissertation were: 
1) To evaluate the role of STRAP behind the altered morphology of STRAP null 
mouse embryonic fibroblasts (MEFs)  
  
During a study to find PDGF target genes using a microarray coupled gene trap 
mutagenesis, STRAP was functionally deleted. The STRAP null mice showed embryonic 
lethality between embryonic day E10.5 and E12.5 with multiple organ system defects. 
The embryonic fibroblasts (MEFs) isolated from STRAP null fibroblasts exhibited 
striking phenotypical alterations. STRAP null MEFs aggregated and formed epithelial 
islands compared to the regular elongated spindle shaped fibroblasts isolated form the 
embryos with same genetic background except for wild type STRAP. This indicated a 
need to study the possible role in maintaining the fibroblastic phenotype of MEFs to get 
additional clues about novel functions of STRAP. The differences between wild type and 
STRAP null MEFS were studied using a variety of techniques and STRAP stable MEFS 
were generated from STRAP null MEFs. A possible role for STRAP in modulating WT1 
expression was identified. 
 
2) To determine the role of STRAP in GSK3β and Notch signaling. 
 
The serine/threonine protein kinase glycogen synthase kinase 3 (GSK-3) is a key 
regulator of multiple enzymes and many important transcription factors. GSK3β 
phosphorylates and thereby regulates the functions of many metabolic, signaling and 
structural proteins.  
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Ewing et al. first (2008) reported the possibility of an interaction between STRAP 
and GSK3β in a large scale analysis of protein-protein interactions using mass 
spectroscopy. We verified this interaction and since STRAP is known to act as a scaffold 
protein in multiprotein assemblies, we decided to study the possible role of STRAP as a 
scaffold in GSK3β signaling. We showed for the first time that intracellular fragment of 
Notch3 is a possible substrate of GSK3β. STRAP also interacted with ICN3 and has a 
stabilizing effect on ICN3 by aiding its deubiquitination. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Cell culture and plasmids 
Wild type and STRAP null mouse embryonic fibroblasts (MEFs), HEK-293, 
HeLa and NIH3T3 cells were maintained in DMEM supplemented with 10% fetal bovine 
serum (FBS), antibiotics, and glutamine (GIBCO BRL).  STRAP null MEFs were used to 
generate clones stably re-expressing STRAP using the STRAP pBabe Puro retroviral 
vector and clones were selected in 0.75 μg/ml puromycin.  The E-cadherin luciferase 
construct (-178/+92) was a gift from Dr. Amparo Cano (Universidad Autónoma de 
Madrid, Instituto de Investigaciones Biomédicas Alberto Sols, Madrid, Spain).  Plasmids 
expressing A and B isoforms of murine WT1 were obtained from Dr. Jerry Pelletier 
(McGill University, Montreal, Quebec, Canada). Axin-myc (in pCDNA3.1) was a gift 
from Dr. Michele Kimple (Duke University). HA-tagged GSK3β (in pCDNA3) and myc-
tagged GSK3β (in pJ3M vector) were gifts from Dr. Gordon Mills (MD Anderson Cancer 
Center) and Dr. Alan Diehl (University of Pennsylvania Cancer Center) respectively. 
Murine STRAP and CT-1-STRAP constructed using the pCDNA3 vector have been 
described previously (Datta et al., 1998). HA-tagged mICN3 and myc-tagged mICN1 
(both in pCDNA3) were a gift from Dr. Jon Aster (Brigham and Women's Hospital, 
Harvard University).   HA-tagged β-catenin was a gift from Dr. Stephen Byers 
(Georgetown University School of Medicine, Washington).  GSK3β inhibitors SB216763 
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and SB416286 were purchased from Sigma and AR-A01441 was purchased from 
Calbiochem and used as directed by manufacturers.  
 
Recombinant adenovirus 
A STRAP expressing adenovirus was generated through homologous 
recombination between a linearized transfer vector pAD-Track and the adenoviral 
backbone vector pAD-Easy (He et al., 1998).  pAD-STRAP contained the full length 
murine STRAP cDNA with a carboxy-terminal HA or FLAG-tag.  In addition to the 
STRAP transgene the virus encoded the green fluorescent protein (GFP) transcribed from 
a second independent CMV promoter.  GFP expression was used to monitor viral 
infection efficiency.  An adenovirus coding for GFP only (pAD-GFP) was used as a 
control in all experiments. For both adenoviruses, a titer of 200 MOI was used in all the 
experiments to infect the cells for 8 hours in a serum free medium. The cells were then 
kept in a serum containing medium for 60 hours where not specifically mentioned. 
 
Western Blot analysis 
For immunoblotting, whole-cell lysates were prepared in a cold lysis buffer with 
0.01 M Tris-HCl (pH 7.4), 0.01 M NaCl, 1 mM EDTA, sodium ortho-vanadate, 0.1 % 
SDS and protease inhibitors (Aprotinin, Leuprptin and PMSF) and sonicated before 
centrifugation at 14,000 rpm for 15 min.  The proteins were separated by 10% 
SDS/PAGE, transferred to nitrocellulose membrane (Biorad), and probed with primary 
antibodies from the following sources: Santa Cruz Biotechnologies (vimentin, WT1, 
fibronectin, HA and Myc), BD Biosciences (E-cadherin, β-catenin and N-cadherin) and 
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Sigma (FLAG) as described in Halder et al., 2006.  Primary antibodies were incubated 
for 3 hr at room temperature followed by incubation with species-specific secondary 
antibodies for 1 hr at room temperature. The signal was visualized by enhanced 
chemiluminescence assay (Amersham Pharmacia Biotech, Pittsburgh, PA). 
 
Co-Immunoprecipitation 
HEK-293T cells were plated in 60 mm dish and transfected next day at a 40% 
confluency with appropriate combination of plasmids using Lipofectamine reagent 
(Invitrogen) using 1:3 ratio in serum-free media. The serum-free media was changed with 
serum-containing media 3 hours after transfection. Where needed, cells were treated with 
proteasomal inhibitor MG132 (4 hr) or GSK3β inhibitors (12 hr) as indicated in 
respective figures. Cells were solubilized in 1ml of lysis buffer (50 mM Tris, 150 mM 
NaCl, 10 mM EDTA, 0.02% NaN3, 50 mM NaF, 1 mM Na3VO4, 0.7% NP-40, 0.5 mM 
dithiothreitol, 0.02% SDS and protease inhibitors aprotinin, PMSF and leupeptin). An 
equal amount of each protein lysate was incubated with the appropriate antibodies as 
indicated in the figures for 3 hours at 4
o
C, followed by incubation with 20 µl of protein 
G-Sepharose beads (dry volume) equilibrated with lysis buffer (Sigma Biochemicals, St. 
Louis, MO) for 1 hour. The immune complexes were washed with the lysis buffer 5 
times. The beads were finally boiled in 50 µl of 2X SDS sample buffer (125mM Tris-
HCL pH 6.8, 20% glycerol, 4% SDS, 2% β-mercaptoethanol, 0.001% bromophenol blue) 
and the samples then were separated on 10% SDS-PAGE and transferred to PVDF 
membranes (Biorad). Bound proteins were analyzed by Western blot analysis using 
appropriate antibody. Protein lysates used for immunoprecipitation were also analyzed by 
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Western blot analysis with other antibodies to check for comparable expression of 
proteins across all transfections. 
 
Reverse Transcription-PCR Analyses 
Total RNA was isolated from each cell line using Trizol method and RT–PCR 
amplification was carried out using MMLV reverse transcriptase.  The RNA samples (2 
μg) were retrotranscribed into cDNA using oligo-dT primers in a total volume of 20 µl 
containing 5 mM MgCl2, 1 mM dNTPs (Boheringer),  1 U RNase inhibitor (Perkin 
Elmer) and 2.5 U MuLV reverse transcriptase (Perkin Elmer) at 37
o
C for 1 hour.  
Amplification by PCR was carried out using 2µl of the cDNA with the Red Taq 
polymerase according to the manufacturer‟s protocol.  The thermal cycles were: 
denaturing at 94
o
C for 1 min, annealing at 54
o
C for 1 min, and extension at 72
o
C for 1 
min. The cDNA was amplified for 28 cycles.  The primer pairs of E-cad, WT1, LEF1, 
Snail, SIP1, Slug, E2A, Twist, S100A and GAPDH are shown in table 1. GAPDH was 
amplified in each sample as an internal control. All experiments were repeated at least 
three times. 
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FITC-Phalloidin staining 
After fixation in 3.7% fresh paraformaldehyde in PBS for 15 min, cells were 
washed twice with PBS, and permeabilized with 0.1% Triton X-100 in PBS for 8 min.  
After treatment with blocking solution (1% BSA and 0.1% Triton X-100 in PBS) for 10 
min, the cells were stained with FITC-phalloidin (1 µg/ml) in blocking solution for 20 
min in a dark room at room temperature to localize F-actin.  The slides were washed 
twice with PBS, each for 10 min.  Incubation and washing were performed in parallel for 
all wells on a slide.  A coverslip was mounted on the slide with Vectashield H-1000 
(Vector Laboratories, Burlingame, CA).  Actin was visualized with a fluorescence 
microscope (Olympus BHT, Tokyo, Japan). 
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Electron microscopy 
Cells were washed with 6.8% saccharose in 0.1 M cacodylate buffer, pH 7.4, at 
room temperature and fixed in 2% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4, at 
room temperature for 30 min.  The cells were rinsed three times in the same buffer with 
6.8% sucrose solution and subsequently postfixed in 2% OsO4/3% K4Fe(CN)6 in 0.2 M 
cacodylate buffer (pH 7.4) at 4°C for 1 h.  After rinsing in 0.1 M cacodylate buffer, pH 
7.4, and dehydration in a graded alcohol series, the cells were embedded in Epon 812 and 
polymerized at 58°C for 64 h.  Finally, ultrathin sections (60 nm) were cut and stained 
with uranyl acetate and lead citrate.  The sections were examined using a Philips CM 12 
electron microscope operating at 80 kV, and micrographs were taken. 
 
Fluorescence Microscopy 
Cells cultured on glass coverslips were fixed with ice-cold methanol in PBS for 
10 min at 4°C, followed by permeabilization with 0.1% Triton X-100 in PBS at room 
temperature for 5 min.  Blocking incubations were performed in PBS containing 3% BSA 
at room temperature for 1 h.  After extensive washes with PBS, cells were incubated with 
the first antibody at room temperature for 2 h.  After washing with PBS, cells were then 
incubated with the corresponding secondary antibody at room temperature for 1 h.  After 
another round of extensive washes in PBS, the coverslips were mounted in a drop of 
mounting medium (Vectashield). The antibodies used were as follows: mouse 
monoclonal anti-E-cadherin and mouse monoclonal anti-β-catenin antibody from BD 
Biosciences, and Alexa Fluor-596 goat anti-mouse from Molecular Probes, Eugene, OR. 
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Reporter Assays 
 
For studying effect of STRAP on WT1-mediated E-cadherin promoter induction, 
NIH3T3 cells, wild type and STRAP null embryonic fibroblasts were plated in 12-well 
plates. After 30 h, luciferase constructs (0.5 μg/well where not mentioned) along with 
expression plasmids for WT1 (100 ng) and/or STRAP (2 doses of 150 and 450 ng) were 
transfected into the cells using Lipofectamine and Plus reagent following the 
manufacturers protocol.  After approximately 48 hours, cells were lyzed and luciferase 
assays were performed using a luminometer (BD bioscience) according to the 
manufacturer‟s protocol.  Transfection of each construct was performed in triplicate in 
each assay and a total of three assays were performed on three separate days.  All wells 
were transfected with 25 ng of beta-galactosidase to serve as a control for the transfection 
efficiency. Ratios of luciferase readings to beta-gal readings were taken for each 
experiment and triplicates were averaged.  Bars represent the averages of the normalized 
values with error bars indicating the standard deviation. 
 
For understanding effect of STRAP on ICN3-mediated transcriptional activation, 
HeLa cells were transfected with HES1 promoter (0.5 µg/well) with different 
combinations of expression plasmids for ICN3 (50 and 200 ng) and/or STRAP (2 doses 
of 100 and 300 ng). Other procedure was exactly as stated above. 
 
Microarray Analysis 
To characterize the gene expression profile of wild type and STRAP null MEFs, 
RNA was isolated from these cells using the Trizol method and further purified using 
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Qiagen RNeasy kit according to the protocol from the manufacturer (Qiagen, Valencia, 
CA).  Microarray was done using GeneChip 430 Mouse 2.0 Array from Affymetrix that 
contains 45,000 probes for analyzing 39,000 variants of 34,000 mouse genes and signal 
intensity was detected according to supplier‟s instructions. 
 
Production of STRAP shRNA lentivirus 
Second-generation VSV-G pseudotyped high titer lentivirus was generated by 
transient co-transfection of 293T cells with a three-plasmid combination as follows: 
One 15 cm dish containing 1x10
7
 293T cells was transfected using Lipofectamine2000 
(Invitrogen) with 5 µg STRAP shRNA lentiviral vector (pGIPZ, Open Biosystems), 3.75 
µg pCMV Δ8.91 and 1.25 µg pMD VSV-G. For vector control lentivirus, empty 
lentiviral vector was used instead of STRAP shRNA lentiviral vector. A shRNA 
construct targeting human and mouse STRAP was obtained from Open Biosystems. The 
21 bp sequence was 5‟-GCTCATGTACTCTCAGGACAT- 3‟. Supernatants were 
collected every 12 hr between 36 to 96 hr after transfection, pulled together and frozen at 
-70ºC. 
 
Lentiviral transduction 
For lentiviral transduction, 1x10
5
 cells were seeded in 6 well tissue culture plates 
and infected the following day with STRAP or vector control lentivirus. The cells were 
then selected for 7 days with puromycin and when cultures reached near confluency, cells 
were trypsinized and processed for FACS analysis to separate cells with highest GFP 
expression. To generate stable STRAP knockdown clones, these cells were plated at high 
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dilutions in 10 cm Petri dishes and colonies obtained from single cells were screened for 
STRAP expression by Western blot analysis. 
 
Immunohistochemical analysis 
Tissue Microarray (TMA) slides containing duplicates of 42 samples of different 
lung carcinomas were obtained from the Lung SPORE project at Vanderbilt University.  
The slides were placed in the sodium citrate solution, microwaved for 45 sec at full 
power, and heated in a pre-warmed steamer for 25min.  After cooling at room 
temperature for 15min, the slides were washed three times with PBS. After antigen 
retrieval, the specimens were treated with 3% H2O2 (DAKO) for 5 min to quench 
endogenous peroxidase activity and a protein block treatment (Dako, Inc.) was performed 
prior to primary antibody addition. Tissues were incubated with anti-STRAP antibody 
(BD Biosciences) at 1:400, anti-Notch3 antibody (Novus Biological) at 1:200. After 
primary antibody incubation, the slides were washed three times with PBS. The 
specimens were then incubated for 10 min at room temperature with biotin labeled goat 
anti-mouse immunoglobulin (DAKO). Slides were lightly counterstained with Mayer‟s 
hematoxylin (Mayer‟s, VWR) for nuclear staining. Afterwards, the slides were 
dehydrated by sequential incubation in 95% ethanol, 100% ethanol and 100% ethanol for 
5 min each, before transferring to xylene and coverslipping. 
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In-vivo ubiquitination Assay 
 
HEK-293T cells were transfected with appropriate combinations of plasmids 
expressing his6-tagged ubiquitin, STRAP-FLAG and HA-ICN3 as indicated. 43 hours 
after transfection, the cells were treated or not with 50 µM of MG132 for 5 hours. The 
cells were then lysed in highly denaturing conditions using 1ml lysis buffer with 8 M 
urea at pH 8. This inhibits the otherwise rapid deubiquitination of proteins by 
deubiquinases after using regular cell lysis conditions. Cell lysates were then sonicated 
and centrifuged at 13,000 rpm for 20 min. A fraction was saved for western analysis and 
remaining was incubated with 50 µl of 50 % slurry of Nickel-Nitrilo triacetic acid (Ni-
NTA) agarose beads slurry for 4 hours on a rocker at room temperature. Ni-NTA beads 
bind to histidine residues of proteins effectively and strongly pull down hexa-histidine 
tagged proteins, his-ubiquitinated proteins in this case. The beads were washed 5 times in 
a buffer with 8 M urea, 20 mM Imidazole kept at a pH of 6.3. This helps to remove 
background of endogenous proteins binding within-NTA beads. His-ICN3 bound with 
the beads were finally eluted with a buffer containing 8 M urea, 250 mM β-
mercaptoethanol (BME) and 200 mM Imidazole at a pH of 4.5. The proteins were eluted 
in 2 batches first with 50 µl and then with 30 µl of elution buffer. The eluates were then 
boiled at 95
o
 C for 6 min with 1X SDS sample buffer and stored at -80
o
 C until further 
analysis. 15 µl of this eluate was analyzed by SDS-PAGE followed by western blotting 
with anti-HA antibody to detect ICN3 species that were ubiquitinated with HA-tagged 
ubiquitin.  
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CHAPTER III 
 
SERINE THREONINE RECEPTOR-ASSOCIATED PROTEIN (STRAP) PLAYS A 
ROLE IN THE MAINTENANCE OF MESENCHYMAL MORPHOLOGY 
 
Introduction 
 
Epithelial and mesenchymal cells represent two distinct cell phenotypes that have 
unique gene expression profiles and functions specific to that cell type.  Compared to 
differentiated epithelial cells, mesenchymal cells do not establish intercellular junctions 
in a stable manner mostly through suppression of E-cadherin expression and this imparts 
them with a higher capacity to detach in response to low shear forces such as within 
lymphatic vessels and venules.  A similar process also decreases the adhesive force in 
epithelial cells during normal embryonic development and during carcinogenesis. 
Epithelial cells located at the periphery of a tumor frequently exhibit a substantial 
downregulation of epithelial markers along with a loss of intercellular junctions and other 
features of epithelial cells, accompanied by expression of a mesenchymal set of genes 
(Lee et al., 2006).  This switch is referred to as epithelial-to-mesenchymal transition 
(EMT).  Practically, it is often difficult to classify cell phenotypes into either extremes 
such as mesenchymal or epithelial and a relative shift from one phenotype to the other 
holds more importance.  A recent study reported phenotypic alterations of the metastatic 
T24/TSU-Pr1 bladder carcinoma line that could express markers of both epithelial and 
mesenchymal type (Chaffer et al., 2006).  A new term „metastable phenotype‟ has been 
coined by Savagner et al. for such cells that continue to express attributes of both 
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epithelial and mesenchymal phenotypes (Klymkowsky et a., 2009).  Such mixed 
phenotypes are being reported more frequently now (Laffin et al., 2008). 
 
EMT provides a mechanism for epithelial cells to overcome the physical barrier 
of intercellular junctions and thus switch to a more motile phenotype.  In many types of 
carcinomas, presence of EMT correlates with poor histologic differentiation, loss of 
tissue integrity and metastasis.  Diverse developmental signaling pathways such as 
epidermal growth factor (EGF), transforming growth factor-β (TGF-β), hedgehog, 
Wnt/β-catenin, Notch and integrin signaling may play a role in the events leading to EMT 
(Mimeault et al., 2007).  Interestingly, a reverse process where mesenchymal cells 
acquire an epithelial phenotype has also been defined and termed as mesenchymal-to-
epithelial transition (MET) (Hugo et al., 2007).  MET occurs during normal 
embryogenesis as well as during re-establishment of metastatic cells at distant sites.  E-
cadherin is known to be upregulated or re-expressed in most of these instances (Wells et 
al., 2008; Baum et al., 2008 and Chaffer et al., 2007).  In vitro, stable expression of E-
cadherin alone has been shown to force the fibroblasts to adopt an epithelial morphology 
(Vanderburg et al., 1996).  Expression of E-cadherin sequesters β-catenin and p120-
catenin to the cell membrane and helps deactivate the mesenchymal cell program (Orsulic 
et al., 1999 and Nelson et al., 2004).  Conversely, absence of E-cadherin frees up β-
catenin that can translocate to the nucleus and activate transcription of a number of 
mesenchymal transcription factors like including c-myc, LEF1, CyclinD1, cdc2 
(Shtutman et al., 1999; Vadlamudi et al., 2005 and Bryan et al., 2003) .  Nuclear 
localization of β-catenin is therefore frequently used as a marker of EMT and indicates a 
poor prognosis in cancer (Lee et al., 2006).  
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E-cadherin thus acts as a master regulator of epithelial phenotype and a 
continuous downregulation of E-cadherin is required in mesenchymal cells (Rubinfeld et 
al., 1997).  This can be achieved through transcriptional as well as post-transcriptional 
mechanisms.  A number of transcription factors such as Snail, Slug, ZEB1, SIP1, E2A, 
and WT1 are known to regulate E-cadherin expression (Batlle et al., 2000; Comijn et al., 
2001; Hosono et al., 2000; Savagner et al., 1997 and Perez-Moreno et al., 2001).  
Interestingly, many of these transcription factors that are important for EMT during 
embryonic development were later found to play a role in EMT during cancer 
progression (Moustakas, et al., 2007).  Yet most of the reports regarding these factors 
have only studied their roles during EMT and little is known about the molecular 
mechanisms important for the maintenance of mesenchymal morphology of fibroblasts 
themselves.  Apart from E-cadherin itself, overexpression of WT1 in NIH3T3 fibroblasts 
has been shown to induce epithelialization with E-cadherin upregulation and formation of 
adherens junctions (Hosono et al., 1999).  Accordingly, absence of MET in kidney is one 
of the main features in the development of Wilm‟s tumor, a rare embryonal malignancy 
which often has deregulated WT1 expression (Li et al., 2002).  More recently, 
overexpression of Versican, a type of proteoglycan, in NIH3T3 fibroblasts and deletion 
of Prkar1a from MEFs has been shown to induce MET (Sheng et al., 2006).  
 
We have previously reported the identification of a novel WD domain protein, 
STRAP, that can bind with TGF-β type I and type II receptors (TβRI & TβRII) and 
inhibit downstream TGF-β signaling through interaction with Smad7 (Datta et al., 1998 
and Datta et al., 2000).  The common function of WD domain proteins is to provide a 
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suitable scaffold for coordinating multiprotein complex assemblies and thus, regulate a 
variety of cellular processes like signal transduction, transcriptional regulation, 
programmed cell death, RNA synthesis/processing, chromatin assembly, cell cycle 
progression and vesicular trafficking (Kashikar and Datta, 2007).  Likewise, STRAP has 
been implicated in a wide array of cellular functions.  Our previous studies suggest that 
STRAP is upregulated in several cancers and functions as an oncogene (Halder et al., 
2006).  Apart from its role in TGF-β pathway, STRAP interacts with PDK1 to positively 
modulate PDK1 activity (Halder et al., 2006).  We have shown that STRAP induces 
extracellular signal-regulated kinase (MEK/ERK) activity in a TGF-β-independent 
manner (Halder et al., 2006 and Seong et al., 2005), and binds with EWS and inhibits the 
interaction between EWS with p300, resulting in a downregulation of EWS target genes 
(Anumanthan et al., 2006).  In a different role, STRAP seems to be involved in the 
assembly of the SMN complex which is necessary for mRNA splicing, through its 
interaction with Gemin6 and Gemin7 as well as SmB, SmD2 and SmD3 components of 
the complex (Grimmler et al., 2005 and Carissimi et al., 2005).  In a relevant interesting 
finding, STRAP along with EWS was shown to be present in the kinesin driven mRNA 
transport granules in the dendrites of murine neurons and also shown to bind with NFX1 
and MAP1B to help export of mRNA out of the nucleus (Tretyakova et al., 2005).  
Homozygous deletion of STRAP gene in mice resulted in embryonic lethality between 
embryonic day (E) 10.5 and 12.5 due to the defects in angiogenesis, cardiogenesis, 
somitogenesis, neural tube closure and embryonic turning (Chen et al., 2004).  A recent 
study suggests that STRAP may be a predictive marker of 5-fluorouracil (5-FU)-based 
adjuvant chemotherapy benefit in colorectal cancer (Buess et al., 2004).  This wide 
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variety of functions of STRAP suggests a broader role for it in tumorigenesis and 
development.  However, nothing is known about of the function of STRAP in 
morphological changes of cells and mechanisms involved in it.  Here, we demonstrate, 
for the first time, that loss of STRAP expression induces a mesenchymal-to-epithelial 
transition through upregulation of E-cadherin.  Furthermore, STRAP-mediated 
downregulation of WT1 may play a role in the regulation of E-cadherin and subsequently 
in the maintenance of mesenchymal morphology. 
 
Results 
 
STRAP Deletion Induces an Epithelial-like Morphological Conversion through 
upregulation of E-cadherin 
 
We have previously reported a role for STRAP in inhibition of TGF-β signaling 
(Datta et al., 2000). We and others have also shown that STRAP is upregulated in lung, 
colon and breast cancer (Halder et al., 2006 and Matsuda et al., 2000).  To determine the 
role of STRAP deletion in mouse embryonic fibroblasts (MEFs), we used STRAP null 
and wild type MEFs that were generated during microarray coupled gene trap 
mutagenesis to find out PDGF target genes.  The gene trap insertion results in embryonic 
lethality between embryonic day E10.5 and E12.5 due to loss of STRAP (Chen et al., 
2004).  We first confirmed the loss of STRAP expression in STRAP null MEFs by 
western blot analysis (Fig 4A).  Interestingly, we observed an obvious morphological 
change in all three STRAP null MEFs, whereas the wild type MEFs maintained 
mesenchymal morphology, as expected.  STRAP null MEFs aggregated and formed 
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epithelial islands with an increased capacity for adhesion to the tissue culture plates (Fig 
4B, top panel).  Two other MEF cell lines isolated from different STRAP null embryos 
showed similar morphological changes (data not shown).  To confirm that the cell 
adhesion and morphological change were due to STRAP loss, we generated and tested 
HA and Flag-tagged STRAP adenovirus as well as the GFP adenovirus (Fig 4A).  
Transient expression of adenoviral HA- or Flag-tagged STRAP reverted the morphology 
of these null MEFs back to the original fibroblastoid type (Fig 4B, bottom panel).  The 
morphological changes in STRAP null MEFs suggested an alteration in intercellular 
adhesion.  Then we analyzed the expression of different epithelial and mesenchymal 
markers including E-cadherin, β-catenin, fibronectin, cytokeratin and vimentin by 
western blot analyses.  Our data showed that E-cadherin expression was significantly 
upregulated in STRAP null MEFs.  Conversely, fibronectin and MMP9 were 
downregulated in STRAP null MEFs and total β-catenin and vimentin showed no change.  
These data suggest that absence of STRAP lead to a partial epithelial transition or a 
metastable phenotype in MEFs. 
 
STRAP null MEFs show polarization at cell organelle level 
 
Together with protein expression changes, changes at cell organelle level often 
accompany phenotypic alterations in cells and tend to have a functional impact on the cell 
characteristics.  Therefore we decided to look at the cell-organelle level to understand 
more about the changes induced by loss of STRAP using transmission electron 
microscopy (TEM).  TEM confirmed the formation of a tightly packed epithelial 
monolayer showing a close alignment of the lateral plasma membranes of adjacent 
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STRAP null MEFs.  It further revealed that the STRAP null MEFs exhibited an apical-
basal polarity, which is a characteristic of epithelial cells.  STRAP null MEFs contained 
numerous electron-dense membranous structures that resembled adherens junctions at 
basolateral border as indicated by the black arrow. The cell-cell interface is indicated by 
white arrowheads (Fig 5A upper 2 panels).  STRAP null MEFs have an apical 
distribution of the Golgi complex (shown by notched black arrowheads) relative to the 
cell nucleus (N) and exhibited microvilli along the apical surface as shown by black an 
asteric. These features were absent in wild type MEFs (Fig 5A middle 2 panels).  TEM 
also showed the presence of multiple electron-dense cytoplasmic fibers running through 
the length of wild type MEFs, indicated by black arrowheads.  These represent the 
cytoplasmic stress fibers that are typical for cells of mesenchymal origin.  These fibers 
are contractile actomyosin bundles that are instrumental in the maintenance of the 
mesenchymal architecture inside cells and facilitate cellular motility.  In contrast, these 
fibers had a more membranous localization in STRAP null MEFs which is typically 
observed in epithelial cells (Fig 5A lower 2 panels).  To confirm this redistribution of 
actin organization, we stained the MEFs with FITC-phalloidin.  As expected, in wild type 
MEFs, F-actin formed parallel cytoplasmic stress fibers whereas actin was mostly 
redistributed towards the cell membrane in the STRAP null MEFs (Fig 5 B).  These data 
suggest that STRAP null cells underwent the process of MET not only in regards to 
changes in gene expression but also showed a consistent change in the cell architecture 
and distribution of cellular organelles.   
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Figure 4: Effect of STRAP on cell morphology.  (A) MEFs, isolated from wild type 
and STRAP null embryos were tested for STRAP expression.  (B) Phase-contrast 
photomicrographs showing that loss of STRAP results in a loss of fibroblastoid 
morphology of the MEFs as cells acquire a epithelial morphology (upper panel).  
Adenoviral transient expression of STRAP can induce epithelial-to-mesenchymal 
transition (EMT) in STRAP null MEFs while a control GFP adenovirus fails to induce 
EMT (lower panel). Adenoviral titer: 200 MOI.  (C) Lysates prepared from wild type and 
STRAP null MEFs were used to study markers of epithelial and mesenchymal 
differentiation.  Western analyses shows upregulation of E-cadherin and downregulation 
of fibronectin and MMP-9 while expression of β-catenin, N-cadherin, vimentin does not 
change significantly. 
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Figure 5. Electron microscopic examination indicates STRAP induces EMT through 
changes at the cell organelle level.  (A) Wild type and STRAP null cells were grown in 
culture on formvar coated coverslips, then fixed with 2.5 % Glutaraldehyde and stained 
with lead citrate and geranyl acetate.  Thin sections were cut using microtome and the 
sections were analyzed using electron microscopy.  Cell-cell interface, indicated by white 
arrowheads, were observed for frequency of adherens junction formation indicated by 
black arrows (upper 2 panels).  In the middle 2 panels, localization of the Golgi complex, 
indicated by notched arrows, was observed for polarization relative to the cell orientation.  
Cell surfaces were observed for microvilli, indicated by a black asterisk.  Finally, in the 
lower panels, cells were analyzed for the pattern and localization of actin (black 
arrowheads).  (N: nucleus). (B) Wild type and STRAP-null MEFs were grown in culture, 
washed with PBS, fixed with 4% paraformaldehyde and permeabilized with 0.1 % Triton 
X.  The cells were then stained with 2 μg/ml of FITC-conjugated phalloidin to map the 
actin arrangement and localization (upper panel).  Nuclei were stained with DAPI (lower 
panel).   
 
 
 
STRAP regulates expression of genes critical for multiple cellular signaling pathways 
and biological processes 
 
In previous studies, STRAP has been implicated to play role in diverse functions 
including TGF-β signaling, mRNA splicing, RNA transport, PDK1 activation etc.  Here, 
we noted that STRAP deletion caused partial epithelialization of MEFs.  So next we 
decided to study the overall impact of STRAP in terms of gene expression regulation in 
MEFs.  Analysis of microarray data using PANTHER Prowler analysis tool confirmed 
that STRAP loss affected sets of genes important for cellular functions like TGF-β 
signaling, growth factor signaling, cell-cell adhesion, cell-matrix adhesion, cell cycle 
regulation and Wnt signaling (Fig 6A).  Analyses of genes affected by STRAP deletion 
were also done after regrouping them according to the overall biological processes they 
are involved with.  These results suggest that STRAP deletion affects biological 
processes such as developmental processes, cell adhesion, signal transduction, mesoderm 
development, cell motility, angiogenesis, oncogenesis etc (Fig 6B). The cellular functions 
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affected by STRAP, including TGF-β/other growth factor and Wnt signaling as well as 
cell-cell/cell-matrix adhesion are known to play diverse roles in the regulation of cell 
morphology. 
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Figure 6. Differential expression of important groups of genes in wild type and 
STRAP null MEFs.  (A) Different gene groups important for diverse functions are 
altered in wild type and STRAP null MEFs.  Wild type and STRAP null MEFs were used 
to isolate mRNA using Trizol method.  Microarray was done using GeneChip 430 Mouse 
2.0 Array from Affymetrix that contains 45,000 probes for analyzing 39,000 variants of 
34,000 mouse genes.  Relative expression of selected genes is shown as a heat diagram.  
Intense red and green colors indicate high and low expression respectively.  (B) 
Biological processes most significantly affected after STRAP deletion were assessed 
based on the whole array of gene expression changes obtained form the microarray 
analysis using PANTHER Prowler analysis tool. 
 
 
 
STRAP downregulates E-cadherin from cellular junctions 
 
To test the specificity of the effect of STRAP on the regulation of E-cadherin 
expression, we generated Flag- and HA-tagged STRAP-expressing adenoviruses and 
tested its expression in wild type and STRAP null MEFs.  We observed that exogenous 
STRAP expression is similar to or less than the endogenous level (Fig 7A).  Next we 
used these adenoviruses to assess the effect of STRAP re-expression on E-cadherin 
expression in STRAP null MEFs.  Adenoviral re-expression of STRAP led to 
B
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downregulation of E-cadherin in a time-dependent manner whereas β-gal adenovirus had 
no effect on E-cadherin (Fig 7B).  To further determine whether endogenous STRAP can 
downregulate E-cadherin from the cellular membrane, we performed 
immunofluorescence staining and examined subcellular distribution of E-cadherin and β-
catenin.  The staining pattern showed that E cadherin was absent in wild type MEFs and 
was seen prominently at the cell-cell junctions in STRAP null MEFs.  Hence we 
speculated that β-catenin would be lost from membranes of wild type MEFs but it would 
be localized to the membranes in STRAP null MEFs.  Indeed, β-catenin was present 
mainly as a diffuse signal in the cytoplasm in wild type MEFs.  By contrast, β-catenin 
was localized predominantly at the cell–cell contacts in STRAP null MEFs (Fig 7C).  
These results are consistent with the total levels of E-cadherin and β-catenin in these 
MEFs (Fig 4C). Collectively, these findings suggest that STRAP regulates E-cadherin 
expression, and in-turn regulates subcellular distribution of β-catenin.  This is significant 
mainly because nuclear β-catenin is considered as an indicator of EMT in cancer cells.  
Since it is difficult to detect nuclear β-catenin by immunofluorescence, the functional 
impact of this E-cadherin loss on nuclear localization of β-catenin was assessed by 
luciferase assays using TOPFLASH and FOPFLASH reporters.  The FOPFLASH is the 
control luciferase vector without any β-catenin binding sites, whereas TOPFLASH has 
three TCF/LEF/β-catenin complex binding sites [41].  These assays indicated that β-
catenin mediated transcription was reduced by 40-50% in STRAP null MEFs when 
compared to wild type MEFs.  Interestingly, transient re-expression of STRAP in null 
MEFs increased TOPFLASH reporter activity (Fig 7D) to levels comparable to wild type 
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MEFs.  Taken together, these data suggest that STRAP induces loss of E-cadherin from 
the membrane that results in nuclear translocation of β-catenin. 
 
 
Figure 7. STRAP inversely regulates E-cadherin expression and induces 
transcriptional activity of β-catenin.  (A) Replication deficient adenoviruses (RDA) 
that are able to transiently express either FLAG-tagged or HA-tagged STRAP were 
generated using AdEasy vector system.  Exogenous expression of STRAP was 
comparable to endogenous expression in wild type MEFs.  (B) Both HA-tagged and 
FLAG-tagged STRAP re-expression in STRAP null MEFs repressed E-cadherin 
expression in a time-dependent manner whereas GFP adenoviral infection did not affect 
E-cadherin expression.  (C) STRAP deletion results in expression and localization of E-
cadherin and β-catenin to the cell membrane.  Wild type and STRAP null MEFs were 
grown in chamber slides, washed with PBS and after fixing with 4% paraformaldehyde, 
they were incubated first with either anti-E-cadherin or anti-β-catenin primary antibody 
and then with cy3-conjugated mouse secondary antibody.  (D) Decrease in β-catenin 
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transcriptional activity by STRAP.  Wild type and STRAP null MEFs were cotransfected 
with two doses (300 and 600 ng) of either wild-type (TOPFlash) or mutant (FOPFlash) 
reporter plasmid and β-galactosidase plasmid with or without increasing doses of STRAP 
expression plasmid.  The total amount of DNA was kept equal.  After 48 h of 
transfection, luciferase activity was determined and normalized to β-galactosidase 
activity. The mean of triplicate luciferase values was used for fold expression 
comparison. 
 
 
 
Stable expression of STRAP in null MEFs rescued the mesenchymal phenotype 
 
Earlier we showed (Fig 4B) a reversion of STRAP null MEFs from epithelial to a 
mesenchymal phenotype after transient expression of STRAP.  In order to validate this 
data, we generated stable clones expressing STRAP in null MEFs.  pBabe-Puro retroviral 
vector with mouse STRAP gene was used and the resulting clones were selected in 0.75 
µg/ml puromycin The expression of STRAP in these stable clones is shown in Fig 10B.  
Three independent clones displayed a reversal from the cobblestone-like morphology of 
STRAP null MEFs to a mesenchymal phenotype (Fig 8).  FITC-phalloidin staining 
revealed that F-actin was organized in parallel stress fibers in these clones (Fig 8) similar 
to wild type MEFs.  Immunofluorescence studies confirmed that E-cadherin expression 
was almost absent and β-catenin was delocalized from the membrane in STRAP stable 
clones (Fig 8).  No effect on E-cadherin and β-catenin and on morphology was observed 
in the vector control clone indicating that stable STRAP expression could specifically 
reverse the MET that occurred in STRAP null MEFs. 
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Figure 8: Stable STRAP expression in null MEFs restores the mesenchymal 
phenotype.  STRAP overexpressing clones (#10, 23 and 25) were generated from 
STRAP null MEFs using STRAP pBabe retrovirus, and selected in 0.75 μg/ml of 
puromycin. These clones reverted to a mesenchymal morphology whereas the vector 
control clone did not show any morphological alterations.  E-cadherin expression went 
down from the membrane and β-catenin was delocalized in the STRAP stable clones.  
Loss of E-cadherin results in actin re-organization from a more cortical form in STRAP 
null MEFs to parallel stress fibers in STRAP stable clones. 
 
 
Transcriptional upregulation of E-cadherin in STRAP null MEFs through 
upregulation of WT1 
 
Regulation of the total E-cadherin pool in a cell is a complex process. It has been 
shown that E-cadherin can be regulated at multiple levels including synthesis, processing 
and stability of mRNA; synthesis and stability of protein; localization and 
posttranslational modification and also binding to the catenins.  So we next decided to 
analyze the mechanism responsible for STRAP mediated regulation of E-cadherin.  
Reporter assays with a mouse E-cadherin promoter luciferase construct showed 
significant upregulation of E-cadherin promoter activity in the STRAP null MEFs 
compared to wild type MEFs.  This upregulation was suppressed considerably when 
STRAP was expressed in STRAP null MEFs indicating that STRAP indeed regulates E-
cadherin at transcriptional level (Fig 9A).  During our analysis of the microarray data, we 
noticed that one of the known inducers of E-cadherin expression, Wilms tumor 1 (WT1) 
was significantly upregulated (3.33 fold) in STRAP null MEFs (Fig 6A).  On the other 
hand, zinc finger transcription factors like Snail, Slug, E2A, Twist, SIP1, and ZEB1 are 
known repressors of E-cadherin expression.  We used RT-PCR to analyze the status of 
the transcriptional regulators of E-cadherin in MEFs.  RT-PCR analyses confirmed that 
 45 
E-cadherin and WT1 mRNA were upregulated in STRAP null MEFs, whereas the 
expression of Snail, Slug, E2A, SIP1, and ZEB1 was not altered in STRAP null MEFs 
(Fig 9B). This suggests that WT1 might be involved in the upregulation of E-cadherin in 
STRAP null MEFs.  Expression of other mesenchymal markers revealed that LEF1 was 
downregulated in STRAP null MEFs whereas FSP1 (S100A) remained unchanged (Fig 
9B).  Free β-catenin is known to go to the nucleus and activate transcription of target 
genes such as LEF1 together with co-factors like the TCF family transcription factors 
(Buess et al., 2004).  This is consistent with our data that β-catenin was localized to the 
membrane of STRAP null MEFs due to upregulation of E-cadherin.  This implies a 
decrease in the nuclear level of β-catenin that can lead to downregulation of LEF1.  
Western analyses confirmed upregulation of WT1 in STRAP null MEFs.  Transient 
adenoviral STRAP expression in the STRAP null MEFs reduced expression of both WT1 
and E-cadherin (Fig 9C).  These data suggest that STRAP-mediated downregulation of 
WT1 may be involved in the regulation of E-cadherin. 
 
Overexpression of STRAP in null MEFs reduces WT1 expression and WT1 activates 
E-cadherin promoter activity 
 
WT1 has been suggested to induce mesenchymal to epithelial transition in the 
metanephric mesoderm during the formation of renal parenchyma. It has already been 
established that WT1 can induce E-cadherin expression in fibroblasts and that stable 
overexpression of WT1 in fibroblasts induced partial epithelialization (Hosono et al., 
1999). Also, mice with Sertoli cells deficient in WT1 show a loss of adherens junctions 
(Rao et al., 2006).  We used STRAP stable clones to test the specificity of the effect of 
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STRAP on the regulation of WT1.  WT1 was downregulated in these clones both in 
mRNA (Fig 10A) and protein (Fig 10B) levels as seen in RT-PCR and western analyses.  
RT-PCR also showed transcriptional downregulation of E-cadherin and upregulation of 
LEF1 in the STRAP stable clones (Fig 10A).  This is in accordance with the decreased 
level of membranous β-catenin that can transcriptionally activate LEF1 expression.  In 
western analyses, total level of β-catenin and N-cadherin did not show any appreciable 
change but fibronectin, an extracellular matrix protein produced by fibroblasts, is re-
expressed in STRAP stable clones as compared to parental STRAP null MEFs or the 
vector control clone (Fig 10B).  
 
Figure 9. STRAP mediates transcriptional downregulation of E-cadherin through 
WT1.  (A) STRAP represses E-cadherin promoter activity.  Wild type and STRAP null 
MEFs were co-transfected with two doses (300 and 600 ng) of murine E-cadherin (-
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178/+92) promoter reporter construct, increasing doses of STRAP expression plasmid 
and β-galactosidase construct.  Luciferase assays were performed and represented as 
described above.  (B) Transcriptional expression of E-cadherin and known regulators of 
E-cadherin was detected by RT-PCR.  Total RNA was extracted from both STRAP null 
and wild type MEFs using Trizol.  After treatment with DNAse 1, cDNA was synthesized 
from RNA and amplified by PCR for 30 cycles using the primers described in Materials 
and Methods.  PCR products were analyzed by agarose gel electrophoresis.  Up-
regulation of E-cadherin and WT1 and downregulation of LEF1 was detected in STRAP 
null MEFs.  (C) STRAP null MEFS were grown in culture and infected with STRAP or 
GFP adenovirus in a serum free media for 6 hours and lysed after another 72 hours. 
Immunoblotting was used to analyze for E-cadherin and WT1 expression along with 
appropriate controls. 
 
 
The WT1 responsive site has been mapped to the GC rich region at about 40 bp 
upstream of the transcription start site in the E-cadherin promoter.  In luciferase reporter 
assays, we observed that both WT1 isoforms A and B successfully induced the E-
cadherin promoter activity (Fig 10C).  This data suggests that STRAP may play a role in 
the downregulation of WT1 in wild type fibroblasts and this in turn affects E-cadherin 
expression.  Interestingly, when microarray data from the wild type and STRAP null 
MEFs was analyzed, STRAP null MEFs showed upregulation of multiple WT1 inducible 
genes like amphiregulin, epiregulin, IGF2, podocalyxibn-like, SOX9 and TIMP3 
suggesting that WT1 is transcriptionally active in these cells (Fig 10D).  Taken together, 
our data indicates that STRAP downregulates WT1 expression in the wild type MEFs to 
suppress E-cadherin expression, and thus maintains the mesenchymal morphology of 
these cells. 
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Figure 10. WT1 can transcriptionally induce E-cadherin expression in fibroblasts.  
(A) The STRAP stable clones and a vector control clone were used to analyze expression 
status of E-cadherin and transcriptional regulators of E-cadherin using RT-PCR as 
described above.  STRAP null and wild type MEFs served as negative and positive 
controls. (B) Western blot analyses were performed to study the expression of E-
cadherin, β-catenin, WT1, fibronectin and N-cadherin in STRAP null and wild type 
MEFs, STRAP stable clones and a vector control clone. STRAP re-expression was 
verified in the stable clones and β-actin was used as a loading control.  (C) Mouse E-
cadherin promoter (-178/+92) was transfected in NIH3T3 fibroblasts with either WT1 A 
or WT1 B expression construct.  Luciferase assays were performed and represented as 
described above. (D) WT1 regulated genes are expressed several fold higher in STRAP 
null MEFs as indicated by microarray analysis. 
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Discussion 
 
Mesenchyme is a loose connective tissue of mesodermal origin.  Fibroblasts, a 
major component of mesenchymal tissue, mainly function to provide structural support to 
all of the body tissues and organs.  During embryogenesis, growth factors secreted by 
migrating fibroblasts as well as the epithelial-mesenchymal interactions in the developing 
tissues are proposed to be necessary for the optimal organ development.  Other functions 
of fibroblasts include but are not limited to wound healing, inflammation, vasculogenesis, 
angiogenesis, fibrosis and regulation of self-tolerance (Haniffa et al., 2009).  Most of 
these functions are in part due to the ability of these cells to effectively migrate to the 
sites of their function.  In addition to their role in normal biological processes, fibroblasts 
can also promote pathological processes.  For example, cancer associated fibroblasts are 
known to accelerate cancer growth by secreting growth factors, promoting neo-
angiogenesis, and ECM remodeling.  These fibroblastic functions are associated with 
increased rates of tumor invasion and metastasis. 
 
The so-called mesenchymal morphology of fibroblasts is thought to be of central 
importance to the much higher migratory ability of these cells.  During normal 
development, the process of EMT provides a means by which epithelial cells can move to 
their appropriate destination tissue by adopting a motile mesenchymal phenotype.  
Downregulation of E-cadherin appears to be a common mechanism for the acquisition of 
mesenchymal morphology, even though the exact mechanism used to downregulate E-
cadherin can be context dependent.  Some of the mechanisms regulating E-cadherin 
expression include transcription, stability of mRNA and protein, subcellular localization, 
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and posttranslational modification.  Importantly, there is a strong clinicopathological 
correlation between decreased E-cadherin expression and tumor dissemination (Kopstein 
et al., 2006).  This finding suggests that EMT is a critical step in progression towards 
invasive and metastatic cancer.  A reverse process known as MET, in which cells with a 
mesenchymal phenotype gain a more adherent epithelial phenotype, is now being 
proposed as a mechanism for the re-establishment of metastatic cells in the distant organs 
(Wells et al., 2008).  Although several studies have identified factors important for the 
EMT, not much is known about the molecular mechanisms vital for maintenance of the 
fibroblastoid morphology of the mesenchymal cells like fibroblasts.  To the best of our 
knowledge, there have been no reports describing the role for STRAP in EMT.  Apart 
from E-cadherin itself, only over-expression of a proteoglycan versican or WT1 is known 
to be able to induce features of epithelial morphology in fibroblasts.  Very recently it has 
been shown that deletion of Prkar1a in MEFs induces MET through upregulation of E-
cadherin expression in fibroblasts (Nadella et al., 2008).  
 
Our present study suggests that expression of STRAP is vital for maintenance of 
fibroblastoid morphology as deletion of STRAP leads to a partial MET in fibroblasts 
though upregulation of E-cadherin (Fig 4B & 4C).  Our electron microscopic studies 
showed that when compared to wild type MEFs, STRAP null MEFs showed increased 
adherens junctions, apically located Golgi apparatus, microvilli on their apical surface 
and a more cortical localization of actin fibers (Fig 5A). These changes are consistent 
with features of epithelial cells. Furthermore, re-expression of STRAP in null MEFs leads 
to downregulation of E-cadherin and to a reversal of the MET.  Compared to wild type 
MEFs, expression of E-cadherin in STRAP null MEFs is elevated at both mRNA and 
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protein level (Fig 4C, 6A and 9C).  The loss of a mesenchymal marker such as 
fibronectin was observed but other markers such as N-cadherin, FSP1 and vimentin did 
not show any change (Fig 4C).  This suggests that the process of epithelialization of 
STRAP null MEFs may be a partial one and fits more with the idea of a „metastable 
phenotype‟ described by Savagner et al.  According to this study, cells can express both 
epithelial and mesenchymal markers when they are in transition. 
 
In an effort to understand the mechanism of E-cadherin upregulation, we studied 
expression of known regulators of E-cadherin expression in wild type and STRAP null 
MEFs.  RT-PCR analyses showed that both cell types expressed similar levels of Snail, 
Slug, ZEB1, SIP1, Twist and E2A mRNA.  However, STRAP null MEFs consistently 
showed elevated expression of WT1 and reduced expression of the mesenchymal marker, 
LEF1 (Fig 9B and C).  It is interesting to note that WT1 is crucial for induction of MET 
in metanephric mesoderm during embryonic development (Davies et al., 2004).  
Additionally, stable WT1 expression in NIH3T3 fibroblasts has been shown to induce 
partial epithelialization with formation of adherens junctions (Hosono et al., 1999).  
STRAP null MEFs demonstrated upregulation of WT1 expression at both mRNA (Fig 
9C) and protein (Fig 10B) levels.  Reporter assays using a murine E-cadherin promoter 
indicated that both WT1 isoforms A and B could induce E-cadherin promoter activity 
(Fig 10C), suggesting a role for WT1 in regulating E-cadherin expression in STRAP null 
MEFs.  STRAP was able to repress E-cadherin promoter activity in STRAP null cells in a 
dose dependent manner (Fig 9A) and this is in agreement with the lower E-cadherin 
message and protein levels in STRAP null cells.  Interestingly, microarray analysis of the 
STRAP null MEFs showed a robust upregulation of multiple WT1 regulated genes 
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including amphiregulin, epiregulin, podocalyxin-like, TIMP3, SOX9 and IGF2 in 
addition to E-cadherin (Fig 10D).  Furthermore, transient adenovirus mediated re-
expression of STRAP was able to downregulate WT1 and E-cadherin in STRAP null 
MEFs (Fig 9C) as well as rescue the mesenchymal phenotype (Fig 4B). 
 
The role of STRAP in the maintenance of mesenchymal morphology was 
confirmed by generating stable clones re-expressing HA-tagged STRAP in STRAP null 
MEFs.  In accordance with transient STRAP expression, stable STRAP expression results 
in a reversion to a mesenchymal morphology (Fig 8).  This morphological change was 
accompanied by suppression of WT1 and E-cadherin expression (Fig 10A and B).  These 
cells show delocalization of β-catenin from the cell membrane and reorganization of 
cortical actin into parallel stress fibers.  These results are in agreement with nuclear 
translocation of β-catenin and with the increase in TOP-FLASH activity (Fig 7D).  This 
may lead to downregulation of LEF1 in STRAP null cells (Fig 9B).  This was further 
supported by the observation that stable expression of STRAP in null cells increased the 
level of LEF1 (Fig 10A).  RT-PCR analyses also confirmed downregulation of both WT1 
and E-cadherin mRNA in the STRAP stable clones.  Chen et al. have found that deletion 
of STRAP in mice leads to an embryonic lethal phenotype between days (E) 10.5 to 12.5.  
The STRAP null embryos have defects in processes such angiogenesis, cardiogenesis, gut 
rotation, somitogenesis and neural tube closure.  It is unclear whether these defects are 
due to some intrinsic defects in the cells of these tissues as a result of STRAP deletion or 
due to the absence of proper stroma and fibroblast function. Further work will be needed 
to arrive at a conclusion.  However, analysis of the microarray data from wild type and 
STRAP null MEFs revealed an alteration of a number of genes important for functions 
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like cell-cell adhesion, cell motility and mesoderm development.  Additionally, STRAP 
deletion also significantly alters the expression of genes (Fig 6A and B) important for 
embryonic development, signal transduction, cell communication and angiogenesis, 
which support the previously published biological functions of STRAP (Datta et al., 
2000; Seong et al., 2005 and Chen et al., 2004).  We also speculate that the balance of 
EMT versus MET in different tissues may be controlled by cell and tissue type–specific 
factors including STRAP and therefore, outcomes of such studies will depend on the 
exact tissue/cell type chosen for that study as previously suggested by the group showing 
MET in Prkar1a-/- MEFs (Nadella et al., 2008).  
 
EMT allows cancer cells to become more motile and invasive. We reported that 
STRAP expression is increased in several cancers including 60% of colorectal, 78% of 
lung and 46 % of breast carcinomas (Halder et al., 2006 and Matsuda et al., 2000).  
Ectopic expression of STRAP in different cell lines promotes cellular proliferation, 
induces anchorage-independent growth and increases tumorigenicity during in vitro and 
in vivo experiments (Halder et al., 2006).  It is possible that STRAP overexpression may 
help tumor cells downregulate E-cadherin in co-operation with other factors known to 
induce EMT, thereby contributing to the increased migratory and invasive ability of these 
cells.  Further work would be needed in this area to determine whether STRAP can play 
such a role in tumor cells. 
 
In summary, we have shown, for the first time, that deletion of STRAP in murine 
fibroblasts is sufficient to cause MET through upregulation of WT1 and subsequently E-
cadherin.  Re-expression of STRAP in these null cells leads to a loss of WT1 and E-
 54 
cadherin expression, and a reversal from epithelial to the mesenchymal morphology.  
Whether STRAP plays a role in EMT in epithelial cancer cells and whether the defects in 
STRAP null mice are from perturbation of cell phenotypes in local tissues or due to 
defect in stromal fibroblasts remains to be seen. 
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CHAPTER IV 
 
NOVEL ROLE FOR STRAP IN GSK3β SIGNALING PATHWAY 
 
Introduction 
 
GSK3β signaling pathway 
 
Originally, GSK3β was named for its ability to phosphorylate and thereby to 
inactivate the glycogen synthase (GS), which is a key regulator of glycogen metabolism. 
GSK-3 is a highly conserved protein kinase and in mammals, GSK-3 is encoded by two 
genes, termed GSK-3α and GSK-3β (Woodgett 1990). These isoforms share almost 
complete sequence identity between their protein kinase domains, but have significant 
sequence differences outside of this region [98% sequence identity in the catalytic 
domain and 84% overall] (Jope and Johnson 2004). The substrate specificity of the 
isoforms is similar but the isoform-specific functions are still unclear. GSK3β knockout 
mice exhibit embryonic lethality, indicating that GSK3α cannot compensate for the loss 
of GSK3β, whereas GSK3β can overcome the loss of GSK3α (Hoeflich et al., 2000).  
 
GSK3β is ubiquitously expressed with a relatively higher level in brain tissue and 
is constitutively active in resting cells or tissues (Ferrer et al., 2002). In contrast to a 
typical kinase, it has been shown that a variety of signaling pathways acting on cells can 
result in a reversible inhibition of its enzymatic activity. Interestingly, most of the 
substrates of GSK3β are functionally inhibited after phosphorylation. This means that 
signals that inhibit GSK3β generally induce the function of GSK3β substrates. GSK3β 
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exhibits very unique substrate specificity. Almost all of the GSK3β substrates are 
required to have a priming phosphate at n + 4 (where n is the site of phosphorylation-a 
serine or threonine residue) to be in turn phosphorylated by GSK3β. Thus, in general, the 
substrate recognition site of GSK3β is -S-X-X-X-Sp-, where Sp is the priming pre-
phosphorylated Serine residue. For example, glycogen synthase (GS) is phosphorylated at 
Ser-656 by casein kinase 2 (CK2) that in turn „primes‟ it to be phosphorylated at Ser-652 
by GSK3β, which in turn primes it again for phosphorylation at Ser-648 and so on until 
five serine residues have become phosphorylated (Cohen and Frame 2001). In a similar 
fashion, eukaryotic initiation factor-2B (eIF2B) is phosphorylated by dual-specificity 
tyrosine-phosphorylated and regulated kinase (DYRK) at Ser-539 prior to GSK3β 
phosphorylation at Ser-535. This however does not hold true for a very small subgroup of 
GSK3β substrates such as Axin that need not be primed to be phosphorylated by GSK3β. 
This is because Axin binds to a distinct site of GSK3β.  
 
Figure 11. Mechanism of phosphorylation by GSK3β. This figure shows an example 
of glycogen synthase, which is primed by casein kinase 2 before multiple serial 
phosphorylations by GSK3β. (From Nat Rev Mol Cell Biol, Oct. 2001, vol 2) 
 
The serine/threonine protein kinase glycogen synthase kinase 3 (GSK3β) is a key 
regulator of many transcription factors. GSK3β phosphorylates and thereby regulates the 
functions of many metabolic, signaling and structural proteins. According to Grimes and 
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Jope (2001), one of the most important roles of GSK3β is the regulation by 
phosphorylation of numerous transcription factors and thereby the control of the 
expression of the respective target genes. These transcription factors regulate genes 
involved in cell growth, cell proliferation, regulation of cellular differentiation and cell 
death such as AP-1, c-Myc, Notch and CCAAT/enhancer binding protein α (C/EBPα). 
The list of putative GSK3β substrates is given in table 2. Some including nuclear factor 
kappa B (NFκB), nuclear factor of activating T cells (NFAT) and heat shock factor-1 
(HSF-1) are involved in the immune system. Data published to date suggest that GSK3β 
plays pivotal roles in the regulation of apoptosis, development, metabolism regulation, 
neuronal growth and differentiation, cell polarity, and cell fate. Since GSK3β is involved 
in such a variety of signaling pathways and cellular functions, it is thought that agents 
that target specific functions of GSK3β may be needed to selectively interfere with 
GSK3β signaling. Towards this, it is necessary to understand how GSK3β regulates its 
many roles in the cell. 
 
Table 2. Putative substrates of GSK3β (Jope and Johnson 2004) 
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Regulation of GSK3β activity 
 
Since GSK3β has a predominant role in the control of several intracellular 
pathways, its activity needs to be carefully regulated. GSK3β is phosphorylated at 
Serine9 that inhibits its activity toward exogenous substrates (Cross et al., 1995). GSK3β 
is also tyrosine phosphorylated within its T-loop region at Y216 (Wang et al., 1994). This 
is considered to be an activating phosphorylation of GSK3β, but modification of this 
tyrosine appears to be the result of an autophosphorylation reaction. Additionally, the 
extent of phosphorylation of this tyrosine residue is always very high in most cells, 
indicating that there is no important regulatory function of this phosphorylation.  
 
Phosphorylation of the N-terminus and subsequent inactivation of GSK3β by 
Protein Kinase B (PKB) in response to insulin signaling is one of the most studied out of 
a number of regulating protein kinases for GSK3β. Insulin signals through its receptor to 
induce the tyrosine phosphorylation of specific adaptor proteins bound to the receptor.  
These adapter proteins then recruit different SH2 and PTB domain proteins to the plasma 
membrane, including the phosphatidylinositol 3′ kinase (PI3K). The PI3K then 
phosphorylates the phosphatidylinositol 4, 5-phosphate, leading to the formation of 3, 4, 
5 phosphatidylinositol (PIP3). This specific phospholipid is limited to the membrane and 
has a high affinity for proteins harboring pleckstrin homology domain such as 
phosphoinositide-dependent protein kinase-1 (PDK1) and PKB. PDK1 then 
phosphorylates PKB after their co-localization at the membrane. PKB in turn 
phosphorylates and inactivates GSK3β (Cross et al., 1995; Jope and Johnson 2004). 
Cyclic AMP-dependent protein kinase (PKA) (Fang et al., 2000), atypical protein kinase 
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C (PKC) (Fang et al., 2002) and p90Rsk (Sutherland et al., 1993) are other protein 
kinases that target the N-terminal domain of GSK3β. 
 
Structural considerations for GSK3β 
As discussed above, most of the substrates need to be primed by another kinase 
before being phosphorylated by GSK3β. For some substrates, the phosphate group added 
by GSK3β acts as a priming phosphate for subsequent phosphorylation by GSK3β, 
leading to serial phosphorylation by it. It is also possible to regulate the processing of any 
GSK3 substrate by regulating the priming kinase activity.  GSK3β comprises an amino-
terminal lobe composed mostly of β-sheets and a carboxy-terminal lobe that is 
predominantly α-helical (Dajani et al., 2001; ter Haar et al., 2001). As discussed above, 
the activation or T-loop of GSK3β is only phosphorylated at a single tyrosine residue, 
Y216. Phosphorylation at this tyrosine residue has little effect on the conformation of 
GSK3β. Consistent with this; removal of the phosphorylated tyrosine does not 
completely inactivate the enzyme. But the binding of the priming phosphate to the 
positively charged pocket made of R96, R180 and K205 residues of GSK3β leads to a 
favorable conformation of the catalytic domain. 
 
As discussed above, phosphorylation of S9 of GSK3β creates a primed 
pseudosubstrate that occupies the catalytic groove and prevents phosphorylation of 
exogenous substrates. The binding affinity of the pseudosubstrate is low so that 
phosphorylated primed substrates can compete off the inhibitory polypeptide at higher 
concentrations (Frame et al., 2001). However, it is the dephosphorylation of the N-
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terminal residue, possibly by a phosphatase termed Laforin that is generally needed to 
reverse the GSK3β inhibition in the cells (Lohi et al., 2005). 
 
GSK3β substrate specificity 
 
Though mitogens and hormones such as insulin negatively regulate GSK3β 
through Ser9 phosphorylation, this mechanism appears to play no role in the regulation of 
GSK3β in the Wnt pathway. It has been observed that cells maintain localized 
subpopulations of GSK3β in such a way that growth factors and hormones that inhibit 
GSK3β through Ser9 phosphorylation have no effect on β-catenin stabilization. Similarly, 
Wnt signaling does not cause changes in GSK3β substrates that are regulated by growth 
factors and hormones such as glucose/glycogen metabolism. This is certainly a very 
critical property of GSK3β as any cross-talk of these pathways can lead to ectopic or 
inappropriate stabilization of key GSK3β substrates such as β-catenin and c-Myc and 
drive cells towards oncogenesis. It seems that protein complex formation and intracellular 
localization are effective ways to regulate this enzyme. The idea that is gaining ground is 
that sequestration of distinct pools of signaling molecules occurs within organizing 
complexes such as A-kinase anchoring proteins (AKAPs) and other scaffolding proteins 
(Carnegie et al., 2009). For example, effective binding of key GSK3β substrates β-
catenin and tau need docking of these substrates to GSK3β by scaffolding proteins like 
Axin and presenilin, respectively. Considering that any inhibitor of GSK3β will inhibit 
access of all substrates to GSK3β rather than just the one substrate critically deregulated 
in a certain disease state, it might be a useful to develop  compounds that target 
specifically the „priming phosphate‟ of specific substrates. 
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GSK3β: Role in Wnt signaling 
 
Wnt proteins are secreted glycoproteins that play key roles in cell growth, 
differentiation, migration, and cell fate determination. N-terminal phosphorylation at Ser9 
plays no role in regulating GSK3β function by the Wnt pathway. GSK3β plays a role 
only in the “canonical” Wnt signaling pathway to tightly control the cytoplasmic levels of 
β-catenin. GSK3β only interacts with β-catenin within the context of a large protein 
complex that comprises GSK3β, β-catenin, the scaffolding protein Axin, and the tumor 
suppressor, adenomatous polyposis coli (APC). In resting cells, GSK3β phosphorylates 
β-catenin at three residues S33, S37, and T41. This targets β-catenin for ubiquitination by 
the E3 ubiquitin ligase βTrCP (Lagna et al., 1999; Winston et al., 1999), and subsequent 
degradation via the 26S proteasome to maintain cytoplasmic and nuclear concentrations 
of β-catenin at extremely low levels. GSK3β mediated phosphorylation of Axin is not 
necessary for its binding with β-catenin but GSK3β mediated phosphorylation of APC 
does increase its binding affinity for β-catenin (Yamamoto et al., 1999; Rubinfeld et al., 
1996). Wnt stimulation leads to a reduction in Axin phosphorylation and disrupts the 
complex formation with GSK3β. This may contribute to Wnt-mediated stabilization of β-
catenin by inhibiting its phosphorylation, leading to its accumulation in the nucleus 
where it transactivates target genes by interacting with LEF/TCF family of transcription 
factors. This is a critically regulated pathway and mutations in scaffold proteins like APC 
occur in 70 % of sporadic colon cancers whereas Axin is mutated in hepatocellular 
carcinomas. Both of these events lead to chronic stabilization of β-catenin (Salahshor and 
Woodgett 2005). 
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Other functions of GSK3β 
 
GSK3β plays a role in glucose homeostasis through its substrate glycogen 
synthase, the rate-limiting enzyme of glycogen synthesis. Insulin inhibits GSK3β through 
PDK to allow for glycogen synthesis. In neurons, GSK3β promotes increased 
microtubule polymerization and axonal outgrowth by inhibiting its substrate collapsing 
response mediator protein 2 (CRMP2) that is known to bind microtubules. 
Phosphorylation of APC by GSK3β acts to destabilize the microtubules as APC is also a 
microtubule binding protein (Zumbrunn et al., 2001). Several other brain-enriched 
structural proteins are GSK3β substrates, including microtubule-associated protein 1b 
(MAP1B) and Tau which is known for its possible role in Alzheimer‟s disease (AD) 
(Maccioni et al., 2001). Apart from β-catenin, GSK3β is shown to phosphorylate c-Myc, 
c-Jun, Cyclin E, Notch, Cyclin D1 and target them for proteolytic degradation through 
ubiquitin-proteasome system (Xu et al., 2008).  
 
 
Notch Signaling Pathway 
 
Notch signaling, conserved from flies to mammals, regulates cell fate decisions 
through direct cell-cell interactions (Lai, 2004). Notch was named so due to the 
indentations (notches) displayed in the wing of mutant flies. Notch signaling is now 
known to regulate a wide variety of developmental processes such as hematopoiesis, 
neurogenesis, miogenesis, wing formation and somite segregation (Lewis, 1998). 
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Notch Signaling in Brief 
 
Notch signaling pathway relies only on a few key components to convey the 
signal from the cell surface to the transcriptional machinery. Binding of ligands from one 
cell to Notch receptors in neighboring cells triggers proteolytic cleavage of Notch 
receptor, which results in a release of the intracellular domain of Notch (ICN) from the 
plasma membrane. ICN then travels to the nucleus and associates with a CSL (CBF-
1/Suppressor of Hairless/Lag-1) DNA-binding protein. This binding converts CSL-
containing complexes from transcriptional repressors to transcriptional activators, and 
thereby changes the transcriptional program of these cells (Fig 12 A) ( Lai, 2004). Apart 
from this, there exists a wide array of modulators of Notch signaling, most of which are 
specific for only a subset of Notch modes of action.  
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Figure 12. Notch Signaling. (A) Schematic view of Notch signaling. Binding of Delta 
ligand on one cell to the Notch receptor on another cell results in two proteolytic 
cleavages of the receptor, releasing the Notch intracellular domain (ICN). ICN enters the 
nucleus helping to recruit co-activator Mastermind and other transcription factors to the 
CSL complex while releasing co-repressors. (From Nat Rev Mol Cell Biol. Sep 2006 vol. 
7) (B) Comparison between Nocth1/2 and Notch3. All three notches have the LIN, ANK 
and PEST domains but there is a controversy whether Notch3 has a functional 
transactivating domain (TAD) or not and therefore represented by a question mark. 
(From Oncogene Sep 2008 vol. 27) 
 
 
 
Structure of the Notch receptors and ligands: The Notch receptor family encodes 
large single-pass transmembrane proteins that are present at the plasma membranes as 
heterodimers. They consist of an extracellular domain and a membrane-tethered 
B
A
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intracellular domain, which share some common characteristic features. On the 
extracellular side, the receptors contain a variable number of tandemly-arranged 
Epidermal Growth Factor (EGF)-like repeats and a family-specific LNR (Lin Notch 
Repeat) (Wharton et al., 1985). The intracellular domain of Notch has four main sub-
domains: the RAM, ankyrin repeat, RE/AC and C-terminal region. The RAM domain is 
believed to mediate direct interaction with CSL, probably together with the ankyrin 
repeats (Roehl et al., 1996). The ankyrin repeats are known to mediate protein-protein 
interactions (Kopan et al., 1994). The C-terminal part is rich in Prolines (P), Glutamic 
acids (E), Serines (S), Threonines (T) and termed as the PEST domain. PEST sequences 
are thought to be important for the ubiquitination and stability of the protein (Greenwald, 
1994). There are two types of Notch ligands, Delta and Serrate. Just like the Notch 
receptors, the ligands are also single-pass transmembrane proteins, with a large EC 
domain containing tandemly arranged EGF-like repeats. There are five characterized 
mammalian ligand homologs: Deltalike1, 3, 4 and Jagged 1 and 2, and four mammalian 
Notch receptors: Notch 1 to Notch 4.  
 
Activation of Notch receptor 
 
 The Notch signaling mechanism is characterized by a series of proteolytic events 
referred to as S1, S2, and S3 cleavages (Aster et al., 1994). The first, S1 cleavage occurs 
in the trans-Golgi network in a constitutive manner by a furin-like convertase before 
receptor is transported to the membrane. Binding of ligand to the Notch extracellular 
domain results in S2 cleavage and releases the majority of the extracellular domain. This 
is mediated by the Tumor Necrosis Factor-Converting Enzyme (TACE), a disintegrin and 
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metalloprotease domain (ADAM) protein in vertebrates (Brou et al., 2000). S2 cleavage 
by ADAM is a necessary step for γ-secretase mediated S3 cleavage. Rapidly following 
S2 cleavage, the membrane anchored Notch receptor is constitutively cleaved at a third 
site (S3) and the signal mediator ICN is released from the membrane. S3 cleavage is 
executed in the transmembrane region of Notch receptor by a large enzymatic complex 
known as γ-secretase complex.  Following S3 cleavage, the intracellular domain of Notch 
translocates to the nucleus and directly induces transcription of downstream target genes. 
ICN can‟t bind to cognate DNA by itself, but interacts with the protein CSL (CBF-
1/Suppressor of Hairless/Lag-1, RBP-Jk) (Tamura et al., 1995), which is a highly 
conserved DNA-binding protein. In the absence of Notch ICD, CSL represses 
transcription (Zeng et al., 2005) by interacting with ubiquitous co-repressor proteins to 
form multi-protein transcriptional repressor complexes, which in turn recruits histone 
deacetylase complexes (HDACs) to the site and convert the local chromatin into a 
transcriptionally silent state. The effects downstream of canonical Notch signaling 
pathway are not completely understood, but two families of basic helix-loop-helix 
transcription factors, Hes and Hey have been well established to be primary downstream 
targets following Notch activation (Sasai et al., 1992; Zhong et al., 2000). These proteins 
are thought to keep the signal-receiving cells in an undifferentiated state. Microarray 
analysis is revealing new Notch target genes such as SKP2 (Dohda et al., 2007), 
interleukin-6, c-Myc (Sharma et al., 2007), Cyclin D1 (Ronchini et al., 2001), p21 
(Rangarajan et al., 2001) and smooth muscle-actin (Noseda et al., 2006). The current 
opinion is that the expression of these target genes induced by Notch activation is highly 
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dependent on the cell context, suggesting that additional specific proteins may be 
involved in regulating their expression.  
 
Regulation of Notch Signaling 
 
To maintain sensitivity to new signaling input, cells need to have effective means 
to tightly control the signaling strength. For Notch signaling, MAML acts as both 
coactivator and terminator for ICN transcriptional activity. MAML directly recruits 
cyclin C:CDK8 complex to the CSL-ICN-MAML transcriptional coactivator complex in 
the nucleus. This is followed by phosphorylation of ICN within the TAD and PEST 
region (Fryer et al., 2004). It has also been demonstrated that Fbw7 (F-box and WD-40 
domain-containing protein 7) is an E3 ubiquitin ligase that induces polyubiquitylation of 
phosphorylated ICN and triggers rapid degradation of ICN by proteasomes (Wu et al., 
2001).  
 
Notch as an Oncogene 
 
Patients suffering from T-cell lymphoblastic leukemia (T-ALL) provided the first 
evidence for an oncogenic function of Notch. About 1% of the cases possess a specific 
chromosomal translocation, t(7;9), resulting in the fusion of the carboxy-terminal region 
from within the EGF-repeat 34 of Notch 1 to the enhancer sequences of the T cell antigen 
receptor subunit (Reynolds et al., 1987) that produces a truncated Notch 1 receptor that 
corresponds to ICN1, which behaves in a constitutively active fashion. More recently two 
types of activating mutations within Notch 1 were found in 55-60% of human T-ALL 
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cases (Weng et al., 2004). The first type occurs in the heterodimerization region and leads 
to ligand-independent activation of Notch receptor. Much more relevant to our work, the 
second type involves the C-terminal PEST region of Notch receptor, resulting in the 
stabilization of ICN.  
 
 Fbw7 is a WD40 domain protein that acts as an ubiquitin ligase implicated in ICN 
turnover (Gupta-Rossi et al., 2001; Wu et al., 2001)). Fbw7 specifically recognizes 
phosphorylated substrates. Sequences recognized by Fbw7 in c-Myc, c-Jun, SREBP1a 
and Notch are phosphorylated by GSK3β, resulting in the ubiquitylation and degradation 
of these proteins (Sundqvist et Al., 2003; Wei et al., 2005). Mutations that abrogate the 
binding of Fbw7 to Notch1 also abrogate its binding to another two characterized targets, 
c-Myc (Yada et al., 2004) and cyclin E (Minella et al., 2005). Stabilization of both ICN 
(intracellular notch) and its principle downstream target, c-Myc, may contribute to 
transformation in leukemias with Fbw7 mutations. ICN1 is also phosphorylated by 
GSK3β. In addition to T-ALL, the most compelling evidence for Notch oncogenic effect 
in other context stems from breast cancer and melanoma. Tissue microarray studies have 
shown that high expression levels of Jagged1 and/or Notch 1 in human breast cancer are 
associated with a more aggressive disease course (Bismar et al., 2006). Notch signaling 
has also been suggested to be required in the hypoxia-induced EMT and cell migration in 
tumor cells. 
 
Just as other Notches, Notch3 plays a role in development indicated by it ability 
to alter cell fate in animals expressing gain-of-function mutants of Notch3 (Dang et al., 
2003; Apelqvist et al., 1999). Most of the studies relating to the role of Notch in cancer 
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focus on Notch1 and little is known about the role of Notch3 in epithelial tumors, such as 
lung carcinomas. Recently, Notch3 was shown to be expressed in approximately 40% of 
resected human non-small cell lung cancers (NSCLC) (Haruki et al., 2005). This is 
significant as Notch3 expression in normal adult lungs is restricted only to the smooth 
muscle cells of blood vessels (Villa et al., 2001). Furthermore, inhibition of the Notch3 
pathway using a dominant-negative receptor dramatically decreased the malignant 
potential of lung cancer cells as evidenced by reduced growth in soft agar and increase in 
growth factor dependence. Treatment of lung cancer cells with a γ-secretase inhibitor 
inhibited Notch3 signaling, reduced tumor cell proliferation and induced apoptosis 
(Konishi et al., 2007). 
 
Recent reports have shown increased expression of Notch3 in T cell leukemias 
and epithelial malignancies arising from pancreas, ovary, breast and lung (Talora et al., 
2003; Miyamoto et al., 2003; Dang et al., 2000; Lu et al., 2004 and Yamaguchi et al., 
2008). It is suggested that Notch3 may play a causative role in these tumors. How Notch3 
is upregulated in these cancers and what is the mechanism for the possible Notch3-
mediated carcinogenesis is not known.  Here we show that STRAP deubiquitinates ICN3 
and may help to stabilize it. STRAP is already known to be upregulated in 78% lung 
cancers and if STRAP is found to be important for Notch stabilization, overexpression of 
STRAP may explain ICN stabilization in some of the cases. 
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Results 
 
STRAP binds to GSK3β through its WD40 domain region 
 
Ewing et al. (2007) were the first to report the possibility of an interaction 
between the scaffold protein STRAP and GSK3β, the classic enzyme in the Wnt and 
insulin signaling pathways. During a large scale analysis of human protein-protein 
interactions using mass spectroscopy, they predicted that STRAP binds with GSK3β with 
a probability of only 0.5. Since they had not validated the binding between STRAP and 
GSK3β, we decided to determine whether STRAP actually interacts with GSK3β using 
co-immunoprecipitation experiments. 293T cells were transfected with myc-tagged 
GSK3β and HA-tagged STRAP using Lipofectamine and Plus reagent according to 
manufacturer‟s protocol. The cells were lysed and the lysates were incubated with either 
anti-HA, anti-Myc or appropriate control IgG antibody followed by incubation with 
protein G-sepharose beads. Figure 13 subpanels A and B show that GSK3β-myc was co-
immoprecipitated along with STRAP-HA and vice versa. Corresponding negative 
controls with either transfection of single plasmid (second and third lanes) or 
immunoprecipitation with a pre-immune Rabbit or Mouse IgG (fourth lane of both 
panels) did not show any co-immunoprecipitated proteins indicating that the binding 
between STRAP-HA and GSK3β-myc was a specific one. 
 
After validating the specific interaction between STRAP and GSK3β, we decided 
to do a preliminary mapping of the region of STRAP that mediates this interaction. We 
tested whether STRAP binds GSK3β through its WD domain region or the C-terminal 
region. We used a STRAP deletion construct that has only the WD40 region i.e. the N-
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terminal 294 amino acids but lacks the C-terminal 57 amino acids (CT1-STRAP). When 
a co-immunoprecipitation assay was performed in a similar way as above, CT1-STRAP-
HA was co-precipitated equally well with GSK3β as the wild type STRAP-HA indicating 
that GSK3β binds STRAP through the WD40 domain region (Fig 13C, lanes 2 & 4). 
Further search to find the exact STRAP region that binds to GSK3β was prohibited by the 
fact that any deletions in the WD40 region have a tendency to make STRAP unstable. 
Together, these results indicate that STRAP specifically associates with GSK3β though 
its WD40 domain region. It is widely known that WD40 domain proteins are involved in 
a range of diverse cellular functions including signal transduction pathways. This is 
achieved by using the WD40 domains as a platform for a stable association of multi-
protein assemblies. We then speculated that STRAP being a WD40 scaffold protein can 
play a similar function in the GSK3β signaling pathway. It is possible that STRAP may 
either recruit an upstream signaling kinase to bind with GSK3β or it can recruit a 
substrate to GSK3β. It is also possible that STRAP may help further processing of the 
substrate after it is phosphorylated by GSK3β. 
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Figure 13. GSK3β and STRAP physically interact with each other. (A) STRAP-HA 
and GSK3β-Myc constructs were transiently transfected into 293T cells. Cells were 
subjected to lysis 48 hours after tranfection, immunoprecipitation using 1 μg of pre-
immuneanti-rabbit IgG or 1 μg anti-HA antibody and immunoblotted with anti-myc 
antibody as indicated. Bottom panels show comparable expression of GSK3β-Myc and 
STRAP-HA in the lysates. (B) Same as above except immunoprecipitations were done 
with anti-mouse IgG and anti-myc antibodies and immunoblotting was done with anti-
HA antibody. All antibodies are from Santa Cruz Biotechnology. Bottom panels show 
comparable expression of GSK3β and STRAP in the lysates. (C) GSK3β interacts with 
the WD40-domain region of STRAP. STRAP-HA, CT1-STRAP-HA and GSK3β-Myc 
constructs were transiently transfected into 293T cells. Immunoprecipitation was done 
with anti-myc and immunoblotting with anti-HA antibody as indicated. Light chain of the 
myc antibody used for immunoprecipitation is visible just below the CT1-STRAP-HA 
band. Bottom panels show comparable expression of STRAP-HA, CT1-STRAP-HA and 
GSK3β-Myc in the lysates. 
 
 
Effect of GSK3β inhibitors on STRAP/ GSK3β binding 
 
EGF, insulin and Wnt signaling regulate GSK3β through the inhibitory Ser9 
phosphorylation medicated by PKA or PKB. However, the mechanism of GSK3β 
regulation in response to other signals is less clear. It is also proposed that different pools 
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of GSK3β exist within the cell to integrate upstream signals with specific downstream 
targets.  
 
To understand if STRAP has any preference towards binding activated or 
inhibited state of GSK3β, we repeated the co-immunoprecipitation assay between GSK3β 
and STRAP in presence of the upstream inhibitor of GSK3β, lithium chloride and three 
other small molecule inhibitors, namely AR-A01441, SB415286 and SB216763. LiCl is 
an ATP noncompetitive inhibitor of GSK3β activity (Ki 2 mM) that has been used 
extensively in studies investigating the functional role of GSK3β (Hong et al., 1997; 
Klein et al., 1997; Stambolic et al., 1996). Lithium ion competes with Mg++ ion that is 
necessary for GSK3β activity. LiCl has also been reported to acutely elevate 
phosphatidylinositol 3-phosphate levels in some cell types, thereby activating PKB 
(Chalecka-Franaszek et al., 1999). Activated PKB phosphorylates and inhibits GSK3β, 
suggesting that LiCl has the potential to inhibit this kinase both directly and indirectly in 
cells. AR-A01441, SB415286 and SB216763 are among the new potent, highly selective 
and cell permeable small molecule inhibitors of GSK3β. These compounds inhibit their 
target protein kinase in an ATP competitive manner (Coghlan et al., 2000). These small 
molecule inhibitors bind to the Val135 and Asp133 residues in the catalytic domain of 
GSK3β and inhibit GSK3β in vitro at 0.01 mM ATP with IC50s less than 100 nM. These 
compounds are highly GSK3 specific and also mimic actions of external inhibitors of 
GSK3β like Insulin as they stimulate glycogen synthesis in human liver cells and also 
mimic Wnt signaling in their ability to induce expression of a β-catenin-LEF/TCF 
regulated reporter gene in HEK293 cells. Figure 14 shows results of the 
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coimmunoprecipitation-western blot experiment between STRAP and GSK3β in presence 
of LiCl and the small molecule inhibitors. 
 
Comparison between lane 2 and lane 6 of figure 14 indicated that lithium did not 
have any notable effect on binding of STRAP with GSK3β suggesting that STRAP may 
not have any dependence on the active or inactive state of GSK3β to bind with it. In 
contrast to this, STRAP binding with GSK3β was reduced moderately in presence of AR-
A014418 and reduced considerably in presence of the other two small molecule 
inhibitors, SB216763 and SB415286 (Fig 14). Since these inhibitors directly bind with 
the catalytic domain of GSK3β, this domain or more likely, the region surrounding the 
catalytic site seems to play a role in the binding of GSK3β with STRAP. There are so far 
no reports showing any unfavorable effect of the small molecule inhibitors on Axin and 
GSK3β interaction. This is expected as Axin binds GSK3β through the C-terminal region 
of GSK3β at a site distant from the catalytic domain.  
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Figure 14. Effect of lithium chloride and small molecule inhibitors of GSK3β on 
STRAP and GSK3β binding. STRAP-HA and GSK3β-Myc constructs were transiently 
transfected into 293T cells. 35 hours after transfection, cells were treated with SB415286 
(20 µM), SB216763 (25 µM) and AR-A014418 (20 µM) as shown in figure. 48 hours 
after tranfection, cells were subjected to lysis, immunoprecipitation using 1 μg anti-HA 
antibody and immunoblotted with anti-myc antibody as indicated. Bottom panels show 
comparable expression of GSK3β-myc and STRAP-HA in the lysates 
 
 
 
Figure 15. STRAP has no effect of the phosphorylation/activation status of GSK3β 
in a panel of cell lines. MEFs from wild type and STRAP null mice were used and 
STRAP was also knocked down in NmuMG, HeLa and HT29 cells using a lentiviral 
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shRNA construct (Open Biosystems). Lysates were prepared and total proteins (30 µg) 
were analyzed for phospho-Ser9-GSK3β, total GSK3β (Cell Signaling) and also β-actin 
as a loading control. (P: parental cells; V: vector control cells; S1 and S2: two STRAP 
knockdown clones, +/+: wild type MEFs and -/-: STRAP null MEFs) 
 
STRAP does not alter phosphorylation/activation status of GSK3β 
 
STRAP binds GSK3β through WD40 domain region. One possible outcome of 
this interaction is that STRAP may regulate signaling upstream to GSK3β. This might be 
achieved by STRAP acting as a scaffold protein to recruit an upstream inhibitory 
regulator of GSK3β such as PKB (Akt) to GSK3β. This will result in phosphorylation of 
GSKβ at Ser9 residue in the N-terminal region. The N-terminal free loop with phospho-
Ser9 can now bind the catalytic site of GSK3β resulting in self inhibition. Although 
GSK3β is also phosphorylated at Y216 that seems necessary for GSK3β activity, this 
phosphorylation is always present constitutively in most cells and does not seem to play a 
significant role in the regulation of GSK3β activity (Cohen and Frame, 2001). We 
decided to test whether STRAP affects activation status of GSK3β in a range of human 
and mouse cell lines. We predicted that a significant change in the total pool of 
intracellular STRAP may alter the activation status of GSK3β if STRAP was crucial for 
mediating signaling upstream of GSK3β. We used the wild type and STRAP null MEFs 
and STRAP knockdown clones derived from HeLa, HT29 and NmuMG cells. Lysates 
from these cell lines were analyzed, as seen in figure 15. Western analyses using the 
phospho-Ser9 specific antibody showed no difference in Ser9 phospohorylation of 
GSK3β in these cell lines. This mostly ruled out that STRAP may affect signaling 
upstream of GSK3β or activation status of GSK3β.  
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Figure 16. STRAP and GSK3β form a ternary complex together with Axin. (A) 293T 
cells were co-transfected with STRAP-FLAG, GSK3β-HA and Axin-Myc in different 
combinations as indicated. Cell lysates were prepared and co-immunoprecipitated with 
2.5 µg of anti-Flag antibody. After 5 washes with the wash buffer, bound proteins were 
eluted using the FLAG peptide (Sigma). The eluate was diluted in the lysis buffer and 
subjected to a second immunoprecipitation with the anti- HA antibody. After washes, the 
bound proteins were eluted and analyzed by western blotting with anti-myc antibody. 
Bottom panels show comparable expression of STRAP-FLAG, GSK3β-HA and Axin-
Myc in the lysates. (B) Same as above except the second immunoprecipitation was done 
using anti-myc antibody and western analysis was done using anti-HA antibody. 
 
 
 
STRAP forms a ternary complex with GSK3β and Axin 
 
GSK3β is responsible for constitutive phosphorylation β-catenin that leads to 
ubiquitination and proteasomal degradation of β-catenin. Scaffolding proteins like Axin 
and APC mediate this recruitment of β-catenin to GSK3β. Deregulation of this pathway 
in colon cancer, where mutations in APC disrupt this complex formation leading to the 
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stabilization of β-catenin and progression of colon cancer. Considering that STRAP may 
play a similar role in recruiting substrates into a complex with GSK3β, we tried to 
determine whether STRAP is present in a complex together with Axin. 293T cells were 
transfected as described above either with all Myc-tagged Axin, HA-tagged GSK3β and 
FLAG-tagged STRAP together or in combinations of two of them together. Lysates were 
prepared similarly and STRAP was immunoprecipitated with anti-FLAG antibody 
(Sigma). After final wash, the protein complexes bound with the beads were eluted with 
300 µl of 1X FLAG peptide (Sigma). The eluants were then subjected to a second 
immunoprecipitation with either anti-HA (Fig 16 left panel) or anti-Myc antibodies (Fig 
16 right panel) to pull down GSK3β or Axin respectively. The proteins eluted after 
second immunoprecipitation were subjected to western analysis for the other protein. The 
results indicate that STARP, GSK3β and Axin formed a ternary complex with each other. 
The role of Axin to recruit β-catenin to GSK3β has been extensively studied. Only 
recently Axin has been shown to aid recruitment of substrates other than β-catenin, such 
as Smad3 to GSK3β (Guo et al., 2008). APC is the other scaffold protein that helps Axin 
to recruit β-catenin to GSK3β. It is possible that STRAP may help Axin in recruiting 
substrates like β-catenin, Smad3 or some yet unknown substrate to GSK3β.  
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Figure 17. STRAP does not interact with β-catenin even in presence of GSK3β 
and/or the proteasomal inhibitor MG132. STRAP-Myc, β-catenin-HA, GSK3β-HA 
and GSK3β-myc constructs were transiently transfected into 293T cells. Where indicated, 
cells were treated with 40 µM of the proteasomal inhibitor MG132 (Sigma) for 5 hours 
before lysis. After this, cells were lysed and subjected to immunoprecipitation using 1 μg 
anti-myc antibody and immunoblotted with anti-HA antibody. Bottom panels show 
comparable expression of STRAP-Myc, β-catenin-HA, GSK3β-Myc and GSK3β-HA in 
the lysates.  
 
 
STRAP does not appear to be involved in β-catenin recruitment to GSK3β 
 
Axin binds directly to GSK3β and β-catenin, through distinct domains at amino 
acids 477–561 and 561–630, respectively (Hsu et al., 1999). Interestingly, apart from 
recruiting β-catenin to GSK3β, Axin also recruits the priming kinase for β-catenin, casein 
kinase 1 (CK1) to the same complex (Liu et al., 2002). This process seems to be highly 
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regulated as other large scaffold proteins like APC are also involved. As STRAP forms a 
complex with GSK3β and Axin, we hypothesized that STRAP may serve as another 
scaffold protein that may help recruitment or processing of β-catenin in the complex with 
GSK3β. MG132 is a peptide aldehyde that inhibits ubiquitin-mediated proteolysis by 
binding and inactivating both the 20S and 26S proteasomes. This is useful in case 
interaction of a particular form of β-catenin with STRAP quickly targeted β-catenin for 
ubiquitin-mediated proteolysis. For example, the half-life of β-catenin is approximately 
100 minutes. This might render the STRAP-binding pool of β-catenin too small to be 
determined by co-immunoprecipitation assays. In such situation, a short treatment of the 
cells before lysis ensures that appreciable amount of this particular form of β-catenin is 
available in the cells for co-immunoprecipitation assays. A similar strategy is often used 
for protein-protein interaction assays of molecules of substrates like c-Myc or c-Jun with 
short half-lives. In co-immunoprecipitation experiments, β-catenin showed binding with 
GSK3β (Fig 17, lane 7) but failed to show any interaction with STRAP in absence or 
presence of a proteasomal inhibitor MG132 or GSK3β (Fig. 17, lanes 3-6) indicating that 
STRAP is unlikely to play any role in recruiting β-catenin to GSK3β. 
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Figure 18. GSK3β binds specifically with ICN3. (A) ICN3-HA and GSK3β-Myc 
constructs were transiently transfected into 293T cells. Cells were subjected to lysis 48 
hours after tranfection, immunoprecipitation using 1 μg pre-immune mouse IgG or 1 μg 
anti-Myc antibody and immunoblotted with anti-HA antibody as indicated. Bottom 
panels show comparable expression of GSK3β-myc and ICN3-HA in the lysates. (B) 
Same as above except immunoprecipitations were done with pre-immune rabbit IgG and 
anti-HA antibodies and immunoblotting was done using anti-myc antibody. The band 
above the GSK3β band is the heavy chain. All antibodies are from Santa Cruz 
Biotechnology. Bottom panels show comparable expression of GSK3β-Myc and ICN3-
HA in the lysates. 
 
 
 
GSK3β binds with Intracellular fragment of Notch3 
 
Earlier reports have shown that GSK3β binds and phosphorylates intracellular 
fragments of Notch1 and Notch2 (Espinosa et al., 2003, Foltz et al., 2002; Jin et al., 
2009). There is no report yet of GSK3β interacting or phosphorylating Notch3 or Notch4. 
Though Notch3 shares an overall good homology with Notch1 and Notch2, they differ in 
certain regions like the transactivating domain (TAD). We used co-immunoprecipitation 
assays in 293T cells after transient transfection to assess interaction of HA-tagged ICN3 
with GSK3β-myc. We successfully showed for the first time that GSK3β interacts with 
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ICN3. This is evident from the 3
rd
 lanes of panels A and B of figure 18. Binding of 
Notch3 with GSK3β predicts that Notch3 is also a substrate for GSK3β. There are 
conflicting reports about the possible outcome of GSK3β mediated phosphorylation of 
Notch1 and Notch2. While some reports indicate that this phosphorylation can stabilize 
Notch, others have claimed that this can accelerate degradation of Notch1 and Notch2. 
For example, a previous report by Foltz et al. (2002) showed that ICN1 interacts with 
GSK3β and was phosphorylated by GSK3β. Their report shows that this phosphorylation 
decreased proteasomal degradation of ICN1 leading to its stabilization. Another report by 
Espinosa et al. (2003) showed that GSK3β binds and phosphorylated ICN2. But in 
contrast, this phosphorylation inhibited the activity of ICN2. Again, a recent report by 
Yun et al. (2009) suggests that ICN1 is negatively, not positively regulated by GSK3β as 
far as stability of protein is concerned. Interestingly, Notch3 stabilization has been 
reported to occur and contribute to the progression of lung cancer. Recent studies also 
suggest that increased Ser9 phosphorylation that inhibits GSK3β, predicts a good 
prognosis for lung cancer patients. It is possible to hypothesize that GSK3β 
phosphorylation may lead to stabilization of Notch3. It will need further work to find out 
the exact role of GSK3β in Notch3 mediated signaling pathway.  
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Figure 19. Generation of HA-tagged ICN3 deletion constructs. Using PCR, we 
generated DNA fragments coding for ICN3 deletion constructs. We added XhoI and XbaI 
endonuclease restiction sites at their ends and subcloned these fragments into the 
pCDNA3.1vector after digesting with XhoI and XbaI. All primers were carefully 
designed to add a HA tag in frame to the C-terminus of the ICN3 fragments. These 
plasmids were used to transiently transfect HEK-293 cells and lysates were analyzed 
using anti-HA antibody.  
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Figure 20. The ANK domain 1863- 2000 aa region of Notch3-IC physically interacts 
with GSK3β. A. HEK-293T cells transfected with 1 µg of HA- GSK3β and various 
deletion constructs of ICN3 as indicated.  The lysates from these cells were incubated 
with anti-HA antibodies for 3 hours and then with G-sepharose beads for 1 hour. 
Complexes were precipitated anti-HA antibody and analyzed by Western blot with anti-
myc antibody to detect GSK3β-myc. Bottom panels show equal expression of the ICN3 
fragments and GSK3β. 
 
 
1880-2000 aa region of Notch 3 is important for GSK3β binding 
 
GSK3β binds to ICN2 through the ankyrin repeat domain, ANK (Espinosa et al., 
2003). The ANK domain of ICN2 has 6 ankyrin repeats and ankyrin repeat 6 is most 
crucial for this interaction. Notch3 has a high homology with Notch2 in the ANK domain 
region. The ANK domain of ICN2 extends from 1824 to 2064 aa and the ANK domain of 
ICN3 extends from 1790 to 2000 aa. The high homology in this region is evident from 
figure 21. We decided to study the region of Notch3 that is necessary for binding with 
GSK3β. For this, we decided to generate serial deletion constructs of the intracellular 
portion of Notch3 from the pCDNA3 mICN3-HA, kindly gifted by Dr. Jon Aster 
(Brigham and Women's Hospital, Harvard University).  
 
The fragments were amplified by PCR, gel purified and digested with restriction 
enzymes XbaI and XhoI. The fragments were ligated in pCDNA3.1 digested with the 
same enzymes. All constructs have a c-terminal HA tag. The expression was verified by 
western analysis (Figure 19). The fragments N1 (1663-2318), N2 (1773-2318), C1 (1663-
2208), C2 (1663-2098), C3 (1663-1988) and C4 (1663-1878) showed comparable 
expressions but the expression from similar amounts of N3 (1883-2318) and C5 (1663-
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1768) fragments was less compared to others. Other N-terminal deletion fragments did 
not show any expression indicating that they might be very unstable.  
 
To study the binding pattern between ICN3 fragments and GSK3β, 293T cells 
were transfected with 1 µg of myc-tagged GSK3β and various amounts of HA-tagged 
deletion fragments of ICN3 to achieve comparable expression level with each other.  
Results from the co-immunoprecipitation assays suggest that the region of ICN3 from 
1883 to 2000 aa is vital for binding with GSK3β (Fig 20). Looking at the high homology 
between ICN2 and ICN3 in the ANK domain, it is possible to predict that the ankyrin 
repeat 6 of ICN3 (1972-2001 aa) might be crucial for the interaction. At the same time, 
the 2010-2120 region seems to have an inhibitory effect on ICN3 and GSK3β binding. 
This inhibitory effect seems to be amplified when this region is freely mobile as C-
terminal tail in the C2 construct.  
 86 
 
 
 
 
 
 
 
 
 
Figure 21. Homology between mouse ICN3 and ICN2. Protein sequences of mouse 
ICN3 and ICN2 were compared and homology is indicated by the common sequence 
placed between the Notch2 and Notch3 sequences. 
 
 
 
Notch3 1612  LGALSAVERLDFPYPLRDVRGEPLEAPEQSVPLLPLLVAGAVFLLIIFILGVMVARRKRE  1671 
             L + +    L   YPL  V  E LE+P ++  LL LL    V +L   +LGV++A+RKR+ 
Notch2 1652  LASHAIQGTLS--YPLVSVFSE-LESP-RNAQLLYLLAVAVVIILFFILLGVIMAKRKRK  1707 
 
Notch3 1672  HSTLWFPEGFALHKDIAAGHKGRREPVGQDALGMKNMAKGES---LMGEVVTD-LNDSEC  1727 
             H  LW PEGF L +D ++ HK RREPVGQDA+G+KN++   S   L+G   ++   D E  
Notch2 1708  HGFLWLPEGFTLRRD-SSNHK-RREPVGQDAVGLKNLSVQVSEANLIGSGTSEHWVDDEG  1765 
 
Notch3 1728  PEAKRLKVEEPGMGAE-EPEDCRQWTQHHLVAADIRVAPATALTPPQGDADADGVDVNVR  1786 
             P+ K+ K E+  + +E +P D R WTQ HL AADIR  P+ ALTPPQ + + D +DVNVR 
Notch2 1766  PQPKKAKAEDEALLSEDDPIDRRPWTQQHLEAADIRHTPSLALTPPQAEQEVDVLDVNVR  1825 
 
Notch3 1787  GPDGFTPLMLASFCGGALEPMPAEEDEADDTSASIISDLICQGAQLGARTDRTGETALHL  1846 
             GPDG TPLMLAS  GG+ + +  E+++A+D+SA+II+DL+ QGA L A+TDRTGE ALHL 
Notch2 1826  GPDGCTPLMLASLRGGSSD-LSDEDEDAEDSSANIITDLVYQGASLQAQTDRTGEMALHL  1884 
 
Notch3 1847  AARYARADAAKRLLDAGADTNAQDHSGRTPLHTAVTADAQGVFQILIRNRSTDLDARMAD  1906 
             AARY+RADAAKRLLDAGAD NAQD+ GR PLH AV ADAQGVFQILIRNR TDLDARM D 
Notch2 1885  AARYSRADAAKRLLDAGADANAQDNMGRCPLHAAVAADAQGVFQILIRNRVTDLDARMND  1944 
 
Notch3 1907  GSTALILAARLAVEGMVEELIASHADVNAVDELGKSALHWAAAVNNVEATLALLKNGANK  1966 
             G+T LILAARLAVEGMV ELI   ADVNAVD+ GKSALHWAAAVNNVEATL LLKNGAN+ 
Notch2 1945  GTTPLILAARLAVEGMVAELINCQADVNAVDDHGKSALHWAAAVNNVEATLLLLKNGANR  2004 
 
Notch3 1967  DMQDSKEETPLFLAAREGSYEAAKLLLDHLANREITDHLDRLPRDVAQERLHQDIVRLLD  2026 
             DMQD+KEETPLFLAAREGSYEAAK+LLDH ANR+ITDH+DRLPRDVA++R+H DIVRLLD 
Notch2 2005  DMQDNKEETPLFLAAREGSYEAAKILLDHFANRDITDHMDRLPRDVARDRMHHDIVRLLD  2064 
 
Notch3 2027  QPSGPRSPSG---PHGLGPLLCPPGAFLPGLKAVQSGTKKSRRPPGKTGL---------G  2074 
             + +   SP G      L P+LC P      LK    G KK+RRP  K+ +           
Notch2 2065  EYNVTPSPPGTVLTSALSPVLCGPNRSFLSLKHTPMG-KKARRPNTKSTMPTSLPNLAKE  2123 
 
Notch3 2075  PQGTRGRGKKLTLACPGPLADSSVTLSPVDSLDSPRPF-----SGPPASPGGFPLEGPYA  2129 
              +  +G  +K  L     L++SSVTLSPVDSL+SP  +     S P  +  G     P   
Notch2 2124  AKDAKGSRRKKCLNEKVQLSESSVTLSPVDSLESPHTYVSDATSSPMITSPGILQASPTP  2183 
 
Notch3 2130  T-----------TATAVSLAQL--------GASRAGPLGRQ--------PPGGCVL-SFG  2161 
                         T  A+S + L        GAS   P   Q        PPG     S G 
Notch2 2184  LLAAAAPAAPVHTQHALSFSNLHDMQPLAPGASTVLPSVSQLLSHHHIAPPGSSSAGSLG  2243 
 
Notch3 2162  LLNPVAVPLDWARLPPPAPPGPSFLLPLAPGPQLLNPGAPVSPQERPP  2209 
              L+PV VP DW           S +  +   P         +PQ RPP 
Notch2 2244  RLHPVPVPADWMNRVEMNETQYSEMFGMVLAPAEGAHPGIAAPQSRPP  2291 
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Figure 22. STRAP binds ICN3 and this binding is significantly upregulated in 
presence of MG132. (A) 1 µg of STRAP-FLAG and ICN3-HA constructs were 
transiently transfected into HEK-293T cells. Where indicated, cells were treated with 40 
µM of the proteasomal inhibitor MG132 (Sigma Biotechnology) for 5 hours before lysis. 
48 hours after transfection, cells were subjected to lysis, immunoprecipitation using 1 μg 
anti-FLAG antibody and immunoblotted with anti-HA antibody. (B) Same as above 
except immunoprecipitation was done using anti-HA antibody and western analysis with 
anti-FLAG antibody. For both A and B, bottom panels show comparable expression of 
STRAP-FLAG and ICN3 in the lystaes. 
 
 
STRAP binding to ICN3 is enhanced in a proteasome inhibition dependent manner 
 
Apart from β-catenin, c-Myc, c-Jun, Notch family proteins and Cyclin E are 
targeted for ubiquitination and proteolysis after GSK3β mediated phosphorylation. Axin 
acts a as a docking protein that allows substrates like β-catenin, Smad3 and even some 
priming kinases like CK1 to be in a complex with GSK3β. Even if STRAP was not 
involved in β-catenin processing, we decided to determine whether STRAP was involved 
in the GSK3β mediated processing of the other GSK3β substrates. It is possible that the 
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abundance of particular docking proteins might, thus, specify different GSK3β functions 
in a cell.  
 
Co-immunoprecipitation assays were done in 293 T cells transfected with FLAG-
tagged STRAP and HA-tagged ICN3 as described above. The cells were treated with 
MG132 or not 43 hours after transfection and lysed 5 hours later. Immunoprecipitations 
were carried out using either anti-FLAG (panel A) or anti-myc (panel B) antibodies. 
Bound proteins were analyzed after running SDS-PAGE and western blotting with 
opposite antibody. Results are shown in figure 22.  It is evident from the second lanes of 
both panels that STRAP effectively binds to ICN3. Interestingly, short treatment with 
MG132 significantly enhanced the interaction between STRAP and ICN3. (lane 3 of both 
panels A and B). As the amount of ICN3 or STRAP present in lysates used for the 
immunoprecipitation is comparable to each other, this finding indicates that the form of 
ICN3 that binds with STRAP might be unstable or rapidly degraded in absence of 
proteasomal inhibition. 
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Figure 23. STRAP binds ICN3 through the same ANK domain region as GSK3β. 
(A) ICN3 deletion fragments C4 and C5 do not bind with STRAP. HEK-293 cells were 
transiently transfected with 1 µg of STRAP-myc and the HA-tagged ICN3 deletion 
constructs in different combinations as indicated. All cells were treated with the 
proteasomal inhibitor MG132 (40 µM) for 5 hours before cell lysis. Cells were lysed 48 
hours after transfection, subjected to immunoprecipitation with 1.5 µg of anti-myc 
antibody and immunoblotted with anti-HA antibody to detect co-immunoprecipitated 
ICN3 deletion fragments. The middle panel indicates the same western blot as in the top 
panel, after stripping and immunoblotting with anti-myc antibody to reveal equal 
immunoprecipitation of STRAP-myc. The bottom 2 panels indicate comparable 
expressions of the ICN3 deletion constructs and STRAP-myc in the lysates. (B) This is a 
reverse of the experiment in panel A. HEK-293 cells were transiently transfected with 1 
µg of STRAP-myc and HA-tagged ICN3 deletion constructs. Lane 1 is a negative control 
transfected only with STRAP-myc. Cell in lanes 3, 5, 7, 9, 11, 13, 15, 17 and 19 were 
treated with 40 µM of MG132 for 5 hours. Cells were lysed 48 after transfection and 
subjected to immunoprecipitation with 1.5 µg of anti-HA antibody. Western analysis of 
the bound proteins was done using anti-myc antibody. Lower panel indicates comparable 
expressions of STRAP-myc and ICN3 deletion constructs in the lysates. 
 
STRAP interacts with ICN3 through the same ANK domain region as GSK3β 
 
STRAP interacts strongly with GSK3β. Since ICN3 binds to both GSK3β and 
STRAP, there is a possibility that STRAP, GSK3β and ICN3 are present in a single 
complex in the cells. To consider this possibility, we decided to determine the region of 
ICN3 that binds with STRAP. We performed coimmunoprecipitation experiments in 
293T cells as discussed above. HA-tagged ICN3 fragments were expressed either alone 
or together with STRAP-myc in presence of MG132. The proteins were pulled down with 
anti-myc antibody and analyzed with anti-HA antibody. We found that ICN3 fragments 
N1 (1663-2318), N2 (1773-2318), N3 (1883-2318), C1 (1663-2208) and C3 (1663-1988) 
demonstrated strong interaction with STRAP in presence of proteasomal inhibitor 
MG132 as evident from lanes 2, 4, 6, 8 and 12 of the figure 23. In contrast, the C2 (1663-
2098) fragment bound STRAP with a relatively lesser affinity (lane 10) whereas 
fragments C4 (1663-1878) and C5 (1663-1768) failed completely to bind with STRAP 
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(lane 14 and 16). This suggested that the 1663-1883 aa region of ICN3 was not important 
for binding with STRAP and loss of 1768-1988 aa region also did not abolish binding of 
STRAP with ICN3. This data suggests that STRAP also appears to bind ICN3 through 
the 1883-2010 aa region which is the same highly conserved ANK domain of Notch3. 
This is the same region that mediates ICN3 binding with GSK3β. Again this is expected 
as this ankyrin repeat region is one of the most adapted motifs for protein-protein 
interactions in Notch3 (Mosavi et al., 2004). Which of the ankyrin repeats in the ANK 
domain mediates this interaction remains to be seen. It also appears that the region from 
2010-2120 aa may have an inhibitory effect on STRAP-ICN3 binding just as the case 
with GSK3β. Taken together, this indicates that STRAP binds with ICN3 through a 
region of 1883 to 2010 which is similar to the overall region of ICN3 crucial to its 
binding with GSK3β.  
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Figure 24. STRAP binds weakly with ICN1. 1 µg of STRAP-HA, GSK3β-HA and 
ICN1-myc constructs were transiently transfected into HEK-293T cells as indicated. 48 
hours after transfection, cells were subjected to lysis, immunoprecipitation using 1 μg 
anti-HA antibody and immunoblotted with anti-myc antibody. Heavy chain band is 
visible just above the GSK3β-myc band. Bottom panels show comparable expression of 
STRAP-HA, GSK3β-HA and ICN3-myc in the lysates. 
 
STRAP binds weakly with ICN1 
 
STRAP binds ICN3 through a conserved region.  Notch1 and Notch2 are the more 
studied members of the notch family that are already known substrates of GSK3β. Since 
all the Notch family members share a high overall homology in the ANK domain, it 
needed to be seen whether STRAP binds only with ICN3 in an exclusive manner or in a 
more generalized manner with other notch members too. In a co-immunoprecipitation 
assay when STRAP-HA was overexpressed in 293 T cells along with ICN1-myc, it was 
seen that STRAP binds with ICN1-myc as evident from the lane 3 of the figure 24. Lane 
2 in the figure is a positive control where ICN1-myc co-immunoprecipiated with HA-
tagged GSK3β. Lane 1 is a negative control with only ICN1-myc expression. Interaction 
with ICN1 may suggest that STRAP plays a more generalized role in notch signaling. 
Further experiments would be needed to delineate the effects of STRAP on ICN1 and 
other notch members like Notch2 and Notch4. 
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Figure 25. GSK3β co-expression does not affect binding between ICN3 and STRAP. 
STRAP-myc, GSK3β-myc, GSK3-HA and ICN3-HA constructs were transiently 
transfected into HEK-293T cells in different combinations as indicated. 48 hours after 
transfection, cells were subjected to lysis, immunoprecipitation using 1 μg anti-HA 
antibody.  Immunoblotting was done with anti-HA antibody. Lanes 3 and 4 show the co-
immunoprecipitation of STRAP with ICN3 in presence and absence of GSK3β-myc 
respectively. Similarly, lanes 2 and 4 show the co-immunoprecipitation of GSK3β-myc 
with ICN3-HA in presence and absence of STRAP-myc.  Bottom panels indicate 
comparable expressions of STRAP-myc, GSK3β-myc and ICN3-HA in the lysates. 
 
 
GSK3β overexpression does not significantly affect binding between ICN3 and STRAP 
 
We have hypothesized that STRAP may act as scaffold protein and may have a 
role in the pre- GSK3β phosphorylation or post- GSK3β phosphorylation processing of 
ICN3. It means that STRAP may actively help to recruit ICN3 to GSK3β in a manner 
similar to Axin helping recruitment of β-catenin to GSK3β. Conversely, if STRAP was 
more important for the post-phosphorylation processing of ICN3, it would be possible 
that presence of GSK would lead to an elevation in the binding affinity of ICN3 towards 
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STRAP. To test this, we conducted coimmunoprecipitation studies between GSK3β and 
ICN3 in the presence or absence of STRAP overexpression. Similarly we also studied the 
binding pattern of ICN3 with STRAP in the presence or absence of GSK3β 
overexpression. To our surprise, we did not observe any effect of either protein on the 
binding of ICN3 with the other partner. The amount of GSK3β-myc co-
immunoprecipitated with ICN3-HA in absence of STRAP-myc (lane 3 Fig 25) or in 
presence of STRAP-myc (lane 4) seems unaltered and similarly the amount of ICN3-HA 
co-immunoprecipitated with STRAP-myc in absence of GSK3β-HA (lane 3) or in 
presence of GSK3β-HA (lane 4). It is possible that the abundant overexpression of ICN3 
compared to the relatively much lower levels found in cells may obscure these studies. Or 
more likely, STRAP can be a part of the multi-protein assembly needed for the 
recruitment of ICN3 to GSK3β. 
 
Figure 26. STRAP decreases ubiquitination of ICN3. HEK-293 cells were transfected 
with 0.8 µg of ICN3 and His6-tagged ubiquitin and 1 µg of STRAP-FLAG in 
combinations as indicated. The cells were lysed in a modified lysis buffer as detailed the 
materials and methods. Proteins tagged with His6-ubiquitin molecules were pulled down 
with Nickel-Nitrilo Tri-Acetic Acid (Ni-NTA) agarose beads. Eluted proteins were 
subjected to electrophoresis and immunoblotting with anti-HA antibody to specifically 
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detect ubiquitinated species of ICN3. Lower panels indicate equal expression of ICN3 in 
the lysates. 
 
 
STRAP decreases ubiquitinated ICN3 
 
STRAP binds with ICN3 and this binding appears to be enhanced in the presence 
of proteasomal inhibition. This suggested that STRAP may preferably bind with the form 
of ICN3 that tends to accumulate when 26S proteasomes are inhibited. This in turn may 
indicate two possibilities. First is that STRAP binds with post GSK3β phosphorylated 
and/or ubiquitinated form of ICN3 and targets it to proteasomes. The other possibility is 
that STRAP may bind ubiquitinated form of ICN3 and help it to be docked to some 
deubiquitinating proteins that can take off the ubiquitin residues of ICN3 to return it to 
the total cellular pool of ICN3. Plasmids expressing FLAG-tagged STRAP, HA-tagged 
ICN3 and hexa-histidine-tagged ubiquitin were expressed in 293T cells in combinations 
as indicated in figure 26. Ubiquitinated proteins in the cell lysates were pulled down with 
Ni-NTA (Nickel-nitrilo triacetic acid) agarose beads. The Nickel binds the hexa-histidine 
residues and pulls down approximately 4 ubiquitinated protein molecules per Nickel. The 
lysates were then washed and eluted proteins were analyzed by western blotting with 
anti-HA antibody. The western analysis shows only ubiquitinated forms of ICN3 as only 
ubiquitinated proteins were pulled down and HA-antibody detects only overexpressed 
ICN3 protein. Lane 3 shows ICN3 was poly-ubiquitinated in absence of STRAP. When 
STRAP was co-expressed, this ubiquitination of ICN3 was significantly inhibited. The 
total expression of exogenous ICN3 remained comparable in the cells as can be seen from 
the bottom panel indicating that the decrease in the ubiquitinated form of ICN3 was not 
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due to a decrease in the total level of overexpressed ICN3. Decrease in ubiquitination can 
have several effects on the functional aspects of a protein, but most commonly it will lead 
to stabilization of the protein in the cell.  
   
 
Figure 27. STRAP does not alter ubiquitination of ICN3 fragments C4 (1663-1878) 
andC5 (1663-1768). HEK-293 cells were transfected with 0.8 µg of ICN3 deletion 
constructs and His6-tagged ubiquitin and 1 µg of STRAP-FLAG in combinations as 
indicated. Rest of procedure was as described above. Top panel shows ubiquitination 
pattern of the Notch3 fragments in the absence and presence of STRAP-FLAG and lower 
panel shows the expression of STRAP-FLAG and Notch3 deletion constructs in the 
lysates.  
 
When a similar experiment was repeated with a few select fragments of ICN3, it 
was observed that STRAP expression decreased ubiquitination of the ICN3 (1663-2318), 
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ubiquitination of fragments 1663-1878 and 1663-1768 (Fig 27). This further supports the 
specificity of the deubiquitinating effect of STRAP as it does not decrease ubiquitination 
of ICN3 fragments it does not bind to.  Taken together, this data suggests that STRAP 
may play a role in stabilization of ICN3 inside cells leading to a decreased turnover or 
longer half life of ICN3 in the cells. This will need a set of careful future experiments like 
S35 labeled pulse chase assays to determine the half life of ICN3 in presence and absence 
of STRAP in the cells.  
 
Figure 28. STRAP inhibits Notch3 mediated transactivation. HEK-293 cells were 
plated in 12 well plates, transfected with 0.5 µg of the HES1-promoter luciferase reporter  
construct and different combinations of ICN3-HA and STRAP-FLAG. All wells were 
also transfected with 20 ng of beta-galactosidase construct. Cells were lysed, luciferase 
activity was normalized using beta-galactosidase activity and averaged for triplicates 
before representing here. The experiment was replicated three times. 
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STRAP decreases ubiquitination of ICN3 and may stabilize it. An increase in the 
half life of the ICN3 protein by STRAP will lead to a larger intracellular pool of ICN3. 
This can possibly lead to an increase in the transcriptional activity by ICN3. We used the 
Hes1-luciferase reporter construct to study the effect of STRAP on ICN3 induced 
transcriptional activity. ICN3 was able to induce the reporter activity in HeLa cells and 
STRAP inhibited this induction in a dose-dependent manner when co-expressed with 
ICN3 (Fig 28). This is a paradoxical effect compared to our initial expectations. But there 
are increasing reports indicating that ubiquitination of some transcription factors helps 
them for certain protein-protein interactions with other transcriptional activators. 
Ubiquitination of Notch IC may facilitate formation of such a transcriptional activation 
complex and may explain why STRAP can decrease ICN3 ubiquitination by and at the 
same time reduce the transcriptional activity of ICN3. 
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Figure 29.  Immunohistochemical analysis of Notch3 and STRAP expression in lung 
cancer TMA. Left hand columns show expression of Notch3 in lung cancer TMA 
(Novus anti-Notch3 antibody). Right hand column shows expression of STRAP in the 
serial section of the same lung cancer samples. All of the positively stained pulmonary 
adenocarcinomas show a predominantly cytoplasmic localization of Notch3 and STRAP, 
whereas the squamous carcinomas exhibit a predominantly nuclear localization of both 
Notch3 and STRAP. 
 
STRAP and ICN3 show significant co-overexpression in Lung Cancer 
 
Previous reports by Haruki et al. (2005) have shown that ICN3 is upregulated to a 
significant degree in lung cancers. STRAP is also overexpressed in 60 % of lung cancers. 
Here we have shown that STRAP binds with Notch in a proteasomal inhibition-
dependent manner and furthermore, STRAP seems to decrease ubiquitination of ICN3. 
These facts when taken together, suggested that STRAP may be one of the factors that 
help stabilization of ICN3 in lung cancer. To test this concept at a preliminary level, we 
stained serial sections of a lung tissue microarray (TMA) with an anti-Notch3 and anti-
STRAP antibodies. The TMA contained duplicate samples from 42 lung cancer patients. 
Sample staining patterns for both STRAP and Notch3 are shown in a pair wise manner in 
figure 29. Each sample on the TMA was scored for the percentage of tumor cells showing 
staining (N) and also the intensity of staining (I). These two numbers were then 
multiplied to get the staining score for each spot. The score for the duplicate spots was 
averaged and then compared pair wise between STRAP and Notch3 staining. Using the 
Pearson‟s pairwise comparison ratio we obtained an overall correlation of 59 % for 
STRAP and Notch3 in the lung cancer TMA. This indicates a highly significant 
correlation between STRAP and ICN3 levels in lung cancer and strengthens the idea that 
STRAP may help to stabilize Notch3 in lung cancer. Interestingly, both STRAP and 
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ICN3 showed a nuclear localization in the two samples form patients suffering from 
squamous cell carcinomas. Conversely, all other samples, mostly adenocarcinomas, 
showed an intra-cytoplasmic localization for both STRAP and ICN3. This favors a cell-
type specific role for the STRAP-ICN3 interaction. This may also result in a differential 
effect of STRAP on ICN3 function in a cell type-dependent manner as far as induction of 
transcriptional activity is concerned. 
 
Discussion 
 
In addition to the roles of STRAP in TGF-β signaling, mRNA splicing and 
transport, PDK1 signaling, EWS signaling, MAPK pathway regulation, maintenance of 
mesenchymal morphology, regulation of GSK3 signaling and Notch signaling are newly 
identified functions of STRAP that are discussed here. It is likely due to the WD40 
domains based rigid scaffold platform that allows STRAP to mediate such a diverse 
protein functions. 
 
We, for the first time, have validated that STRAP interacts with GSK3β, a kinase 
that regulates phosphorylation of a great variety of proteins including but not limited to 
enzymes and transcription factors (Fig 13). Looking at the list of its validated substrates, 
GSK3β appears to be at the cross roads of diverse cellular signaling pathways. 
Considering the limited pool of GSK3β that would be available in a cell at a given time, 
it is not well understood how GSK3β would regulate certain pathways selectively in a 
cell and time-dependent manner and be able to insulate other pathways at the same time. 
The emerging theme is that the abundance of various scaffold or docking proteins in a 
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cell will decide what substrates and subsequently pathways are being regulated by 
GSK3β in that particular cell. Axin/APC mediated docking of β-catenin and presenilin-
mediated docking of tau protein are very well known examples of such mechanisms (Hart 
et al., 1998; Takashima et al., 1998). Based on the fact that STRAP being a novel 
scaffold protein that binds GSK3β through WD40 domains raises a possibility that 
STRAP may have a similar role in processing of one or a few of the GSK3β substrates. 
The ability of STRAP to form homo-oligomers can further enhance the possibility of 
such a role for STRAP.  
 
Known scaffold proteins in GSK3β signaling namely Axin, APC and presenilin 
are all phosphorylated by GSK3β. Possibility of GSK3β mediated phosphorylation of 
STRAP needs to be tested with careful kinase assays. Though STRAP is phosphorylated 
through the C-terminal free tail by a hitherto unknown kinase, this phosphorylation is 
unlikely to play any role in STRAP-GSK3β binding as STRAP binds GSK3β through its 
WD40 domain and C-terminus of STRAP is dispensable for this. Use of eukaryotic linear 
motif (ELM) functional site prediction software to predict specific phosphorylation sites 
suggests that STRAP does have six probable GSK3β phosphorylation sites at 69-76, 102-
109, 137-144, 172-179, 198-205 and 281-288, all in the WD40 domain region. Point 
mutational studies would be needed to confirm their phosphorylation by GSK3 in vivo. 
Even with the possibility of such a phosphorylation, it may or may not play a role in 
binding of STRAP with GSK3β. It is known that phosphorylation of Axin does not affect 
its binding ability with β-catenin but phosphorylation of APC does enhance APC‟s 
binding with β-catenin several fold (Yamamoto et al., 1999; Rubinfeld et al., 1996).  
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In another completely novel finding, we observed that STRAP, GSK3β and Axin 
can form a triple complex together (Fig 16). Interaction of STRAP with these two classic 
mediators of Wnt signaling pathways would indicate a possible role for STRAP in β-
catenin processing. But our assays do not support this possibility as STRAP failed to 
interact with β-catenin in absence or presence of GSK3β or the proteasomal inhibitor 
MG132 (Fig 17). Recently, however, the role of Axin in GSK3β signaling has been 
shown to be more versatile as it also recruits Smad3 to GSK3β (Guo et al., 2008). Smad3 
is phosphorylated and degraded as an effect of GSK3β phosphorylation. This finding can 
imply that Axin may play a similar role for other known and yet unknown substrates of 
GSK3β. Just as APC acts as an additional scaffold to recruit β-catenin to GSK3β, STRAP 
may play a similar role in recruiting or processing of Smad3 or other yet unknown 
substrates to GSK3β together with Axin. Consistent with this, previous studies have 
already shown that STRAP interacts with Smad3 and MAP1B, another known substrate 
of GSK3β (Datta et al., 1998; Iriyama et al., 2001). 
 
Notch1 and Notch2 are among the validated substrates of GSK3β. Though 
Notch3 shares a high homology with Notch1 and Notch2 in some regions, the N-terminal 
and C-terminal regions of ICN3 are considerably different from ICN1 and ICN2. We for 
the first time show that ICN3 also interacts strongly with GSK3β, raising a possibility 
that it is another substrate of GSK3β (Fig 18). Using serial deletion constructs of ICN3 
we have mapped the 1880 to 2000 aa region of ICN3 to be crucial for mediating the 
interaction with GSK3β (Fig 20). This region falls within the ANK domain of ICN3 that 
is made of 6 ankyrin repeats. Ankyrin repeat is one of the most widely existing protein 
motifs in nature (Mosavi et al., 2004). It consists of 30-34 amino acid residues and 
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exclusively functions to mediate protein-protein interactions, further validating the region 
we mapped in our studies. The Notch family members exhibit a very high homology with 
each other in the ANK domain compared to other regions. Our finding is also consistent 
with a previous study showing that the ankyrin repeat number 6 in the ANK domain of 
ICN2 mediates the interaction of ICN2 with GSK3β (Espinosa et al., 2003). Further 
studies with targeted deletions in ICN3 will be needed to see if the same ankyrin repeat is 
involved in GSK3β and ICN3 binding.  
 
Similarly, further work in the form of kinase assays and point mutational studies 
will be needed to confirm that ICN3 is a bona fide substrate of GSK3β. But considering 
the very high homology of Notch3 with Notch2 in this region and the fact that ICN2 is 
phosphorylated by GSK3β in the same region; it seems highly probable that ICN3 might 
be phosphorylated by GSK3β. GSK3β being a serine threonine kinase, phosphorylates 
Notch2 in the STR (serine threonine rich) domain that immediately follows the ANK 
domain on the carboxy terminal side. Ser-2093, Thr-2074 and Thr-2068 or Ser-2070 are 
the three residues phosphorylated by GSK3β in ICN2. Similarly, ICN1 has been known 
to be phosphorylated by GSK3β and a recent report proposes that GSK3β phosphorylates 
ICN1 through the same STR region at residues Thr-1852, Thr-2123 and Thr-2125 (Jin et 
al., 2009). Analysis of ICN3 using eukaryotic linear motif (ELM) functional site 
prediction software revealed four putative GSK3β phosphorylation sites in the same STR 
domain of ICN3. These consensus sequences are MQDSKEET (1968-1975), 
DQPSGPRS (2026-2033), ADSSVTLS (2094-2101) and VTLSPVDS (2098-2105). 
Which and how many of these sites are actually phosphorylated by GSK3β will need 
 105 
further work in the form of precise kinase assays with ICN3 point mutations and deletion 
constructs. 
 
A previous study found that GSK3βmediated phosphorylation destabilizes ICN1 
while another study found that the same phosphorylation seems to have a stabilizing 
effect on ICN1, inducing its transcriptional activity (Foltz et al., 2002; Jin et al., 2009). In 
the light of conflicting data about the outcome of GSK3β-mediated phosphorylation of 
Notch1 protein, the exact effect of this interaction of ICN3 with GSK3β and the probable 
outcome GSK3β-mediated phosphorylation may be complicated to predict. But 
considering that the GSK3β-mediated phosphorylation of other transcription factors 
including β-catenin, c-Myc, c-Jun, Snail, Notch2, HIF-1α etc. and also Notch1, 
destabilizes and inhibits them, it can be predicted that GSK3β may have a similar 
inhibitory effect on ICN3.  In other words, GSK3β-mediated phosphorylation would 
probably lead to ubiquitination and proteasomal degradation of ICN3.  
 
After finding that STRAP did not seem to bind with β-catenin, we looked at any 
possible interaction of STRAP with ICN3 as it was one of the new probable substrates of 
GSK3β we had found. Our results suggest that STRAP interacts with ICN3 (Fig 22). This 
might add STRAP to the list of known WD40-domain proteins like β-TRCP and Fbw7 
that help to process substrates of GSK3β. These WD40 proteins bind these substrates 
only after they are phosphorylated by GSK3β. This is achieved through the WD40 
domains that are considered to be very efficient for recognizing post-translational 
modification and especially phosphorylation. On a similar note, it is conceivable that 
STRAP may bind ICN3 only after specific residues have been phosphorylated by 
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GSK3β. Currently we do not have any evidence for or against this possibility. Further 
understanding may come after confirming the phosphorylation sites for GSK3β and 
performing co-immunoprecipitation experiments with the specific ICN3 point mutants.  
 
But in an interesting observation, we noted that the interaction between STRAP 
and ICN3 was significantly enhanced when the cells were pretreated with the 
proteasomal inhibitor MG132 for a short period of time (Fig 22). Treatment with MG132 
is usually employed when a particular form of the protein that may be more relevant to 
certain investigation rather than the total protein pool, is being degraded rapidly. The half 
life of Notch3 was calculated to be 0.7 days or approximately 17 hours (Takahashi et al., 
2009). So a pretreatment of the cells for 5 hours may not lead to a significant elevation in 
the total ICN3 protein but it can possibly lead to a relatively higher accumulation of the 
fraction of the total level of ICN3 protein that is being rapidly degraded by proteasomes 
after ubiquitination. This data may just indicate that the phosphorylated form of ICN3 is 
degraded rapidly after phosphorylation. Accumulation of this phosphorylated form of 
ICN3 in an ubiquitinated or non-ubiquitinated form seems to have significantly enhanced 
ability for binding with STRAP. There is still a chance that this data may suggest that 
STRAP can also preferentially bind to a form of ICN3 that was ubiquitinated. In this 
case, whether STRAP may bind to a mono-ubiquitinated form or a poly-ubiquitinated 
form of ICN3 is difficult to predict. Ubiquitination of a protein substrate involves a 
cascade of enzymatic reactions. First, Ub, a highly conserved 76-amino acid polypeptide, 
is activated by an Ub-activating enzyme (E1), leading to ATP-dependent formation of a 
high energy thiol ester bond between the C terminus of Ub and E1; the activated Ub is 
then transferred to an E2 enzyme (Ub-conjugating enzyme or Ubc). E2 enzymes then 
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mediate the transfer of Ub to the target protein directly or to E3 Ub protein ligases, which 
are responsible for substrate recognition and for promoting Ub ligation to substrate. A 
substrate may be repetitively ubiquitinated by sequential linkage of additional Ub 
molecules to form a poly-(Ub) chain (Hochstrasser, 2009). This marks the protein 
substrate for recognition and consequent degradation by the 26 S proteasome. But 
considering that ubiquitination is a relatively very large post-translational modification 
and also that there are no reports about a WD40 domain being able to recognize an 
ubiquitinated protein, it is more likely that STRAP may bind with the phosphorylated 
form of ICN3 rather than an ubiquitinated form. Ubiquitination of this phosphorylated 
form of ICN3 may not have any effect on its binding ability with STRAP. As in case of 
GSK3β, the binding between STRAP and ICN3 appears to be through the 1883-2010 aa 
region that is known as the ANK domain (Fig 23). This can be expected since the ankyrin 
repeats in this domain are one of the most ideal modules for protein-protein interactions. 
The ANK domains of Notch proteins have 6 ankyrin repeats. GSK3β binds Notch2 
through the 6
th
 ankyrin repeat. Since the first 2 repeats occur before 1883 aa and GSK3β 
itself binds to the 6
th
 repeat, STRAP may possibly bind Notch3 through the ankyrin 
repeats 3-5.  
 
Notch3 ANK region retains a high homology between the members of Notch 
family. This was reflected in the ability of STRAP to bind ICN1, indicating that STRAP 
may play a more generalized role in notch signaling rather than just Notch3-mediated 
signaling (Fig 24). But our initial assays have also indicated that binding of STRAP with 
Notch1 was somewhat weaker than Notch3. How this might affect the role of STRAP in 
Notch1-mediated signaling when compared to Notch3 signaling is not known. To 
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understand the overall impact of STRAP on notch signaling will need additional studies 
between STRAP and Notch1, Notch2 and Notch4. 
STRAP seems to interact with a form of ICN3 that may be rapidly degraded. So 
when we looked at the effect of STRAP on the ubiquitination of ICN3, STRAP 
consistently decreased Notch3 ubiquitination (Fig 26). We hypothesize that STRAP can 
either carry a phosphorylated ICN3 to a phosphatase to remove the phosphate group and 
avoid ubiquitination or later in the process dock it to an ubiquitin specific protease after 
ICN3 has already been ubiquitinated. This has been found to be the case for β-catenin. It 
was shown that PR55α, the regulatory subunit of protein phosphatase 2A (PP2A), 
controls β-catenin dephosphorylation and degradation (Zhang et al., 2009). Very 
surprisingly, PR55α is a WD40 domain protein with 7 WD40 repeats just like STRAP. 
Same report also showed that PR55α interacted with both β-catenin and Axin. This 
strengthens a chance of a similar role for STRAP and raises a possibility that STRAP 
may act as a regulatory subunit for a phosphatase like PP2A. A more detailed knowledge 
of Nocth3 phosphorylation sites and availability of phospho-specific antibodies will be 
necessary for additional experiments in this regard. On a similar note, c-Myc is also 
targeted to PP2A to remove the primed phosphate group but not the GSK3β mediated 
phosphorylation. PP2A regulatory subunit, B56α has been identified to play this role 
(Arnold and Sears, 2006).  B56α, though is not a WD40 domain protein. Targeting the 
substrates to the respective phosphatases can be a rate limiting step in such a process, 
thus driving majority of the substrate towards ubiquitination and only a fraction of 
phosphorylated substrate might be returned back to the cellular pool in the absence of the 
scaffold protein to dock the substrate to the phosphatase. If STRAP helps such targeting 
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of the phosphorylated ICN3 to a specific phosphatase, it can inhibit the ubiquitination and 
proteasomal degradation of ICN3. 
Another plausible explanation appears to be that STRAP can recruit the 
ubiquitinated ICN3 to a deubiquitinating enzyme (DUB). Ubiquitination of target 
proteins is reversible process and the removal of Ub can rescue proteins from degradation 
or re-modulate their activity. The deconjugation of ubiquitin involves removing the 
covalently linked ubiquitin molecules and is accomplished by the deubiquitinating 
enzymes (DUBs). The majority of the approximately 100 DUBs in the human genome 
belong to the ubiquitin specific protease (USP) subclass of DUBs and others belong to 
the ubiquitin C-terminal hydrolase (UCH) subclass. Structurally, USPs contain a common 
catalytic domain that consists of two short well-conserved motifs, called Cys and His 
boxes. Deubiquitination by USPs has been established as an important aspect of many 
cellular processes (Hurley et al., 2006). Though such a deubiquitinating protein has not 
been identified for Notch proteins yet, there are several reports demonstrating such a role 
for USPs. An example for such case is c-Myc, a vastly studied substrate of GSK3β. c-
Myc is phosphorylated by GSK3β on Thr-58 after it has been phosphorylated by ERK on 
Ser-62 (Gregory et al., 2003). This doubly phosphorylated form of c-Myc is then carried 
by Fbw7 to the E3 ubiquitin ligase complex SCF (Skp, Cullin, F-box containing 
complex) to be ubiquitinated and then destroyed by proteasomes  (Welcker et al., 2006). 
But there are additional levels of regulation even after c-Myc is phosphorylated by 
GSK3β. The same E3 ubquitin ligase component Fbw7 can also dock ubiquitinated c-
Myc to an ubiquitin specific protease, specifically USP-28 (Popov et al., 2007). This 
leads to de-ubiquitination of c-Myc and it is returned back to the cellular pool. STRAP 
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might play a similar role for Notch3, though STRAP may not regulate Notch3 in a dual 
manner as Fbw7 regulates c-Myc. 
Yet another possibility is that STRAP may act just by the mechanism of steric 
hindrance.  In this scenario, binding of STRAP with ICN3 will not allow ICN3 to bind 
with its two known E3 ubiquitin ligases namely, Fbw7, a component of an SCF-class 
ubiquitin ligase (E3) complex and Itch, a Hect-type E3 ubiquitin ligase (Qui et al., 2000). 
Interaction of ICN3 with these substrate specific components of E3 ubiquitin ligases is 
crucial for docking ICN3 to these complexes for ubiquitination.  Consistent with this 
idea, in the case of c-Myc, it was shown that when only the WD40 domain region of 
Fbw7 was overexpressed without the remaining c-terminal 350 aa, it acted in a dominant 
negative fashion to inhibit Fbw7 activity and stabilized c-Myc (Welcker et al., 2006). 
STRAP has 7 WD40 domains just as Fbw7 but naturally lacks the large c-terminal region 
observed in Fbw7 and thus may act in a dominant negative fashion to inhibit 
ubiquitination and subsequent degradation of ICN3 by Fbw7. Future experiments will be 
needed to resolve these issues.  
 
Irrespective of the mechanism, deubiquitination of ICN3 mediated by STRAP 
may lead to stabilization of ICN3 in the cells. This will reflect in a longer half life for 
ICN3 in presence of STRAP compared to when STRAP is absent in the cells. Future 
experiments will include radioactive S35 and cycloheximide pulse chase assays after 
knocking down STRAP in some lung cancer cell lines like HCC2429, H1418, H1435 or 
H1993 that have detectable levels of ICN3.  
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Dang et al. (2000) first showed that level of ICN3 was significantly upregulated in 
samples of human lung carcinomas when compared to the surrounding normal lung tissue 
from the same patients. Overexpression of Notch3 later was shown to contribute towards 
the tumorigenic behavior of the lung cancer cell lines (Haruki et al., 2005; Konishi et al., 
2007). The exact mechanism behind this Notch3 upregulation was not known. We know 
that STRAP is upregulated in 78% of lung cancers. Since our current work indicates that 
STRAP may stabilize ICN3, we hypothesized that STRAP upregulation may be one of 
the possible causes behind the stabilization and subsequent upregulation of Notch3 
observed in lung cancer patients. Immunohistochemical staining of tissue micro array 
(TMA) with duplicate serial sections of lung tumors showed that STRAP and ICN3 were 
co-overexpressed in about 60% of all samples using the Pearson‟s pairwise correlation 
ratio (Fig 29). This is a very interesting but yet a preliminary finding. Further work will 
be needed to assign a causative role for STRAP in upregulation of ICN3 in lung cancer.  
 
The localization pattern for both STRAP and ICN3 was mostly cytoplasmic and 
only slightly nuclear in the majority of the stained lung tumors. But in an interesting 
observation we found that only in the squamous carcinomas, both ICN3 and STRAP had 
a distinct nuclear localization. The reasons behind this are unclear at this time but 
emphasize a cell type-dependent role for STRAP in Notch3 signaling. It remains to be 
seen whether STRAP can stabilize ICN3 in the nucleus. A previous report has shown that 
squamous carcinomas of the cervix had a much higher nuclear distribution of ICN3 when 
compared with cervical adenocarcinomas (Yeasmin et al., 2010). Nuclear ICN3 was 
shown to be associated with adverse clinical outcome. Another study reported that 
immunohistological staining of pancreatic adenocarcinomas showed both cytoplasmic 
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and nuclear staining patterns. Again, statistical analysis suggested that nuclear 
localization of ICN3 was associated with a more aggressive tumor phenotype and a 
poorer prognosis (Doucas et al., 2008). It would be interesting to find the STRAP 
localization pattern in these cervical and pancreatic cancers. 
 
The possibility of ICN3 stabilization by STRAP suggested that STRAP might be 
able to affect Notch3-mediated transcriptional activity. We expected that STRAP will be 
able to induce the transactivating ability of ICN3. Surprisingly, we found that STRAP 
was able to inhibit Notch3-induced activation of the HES-1 promoter in a dose-dependent 
manner (Fig 28). A deeper look into the newer emerging roles of protein ubiquitination 
enables us to explain our observation. Apart from novel functions like membrane 
trafficking, endocytosis, cell-cycle control, protein kinase activation and DNA repair, 
ubiquitination of some transcriptional factors is now being reported to be crucial for their 
transactivating ability (Chen and Sun, 2009). For example, during tumorigenesis, Lys-63-
linked polyubiquitination of the transcription factor Myc by the E3 ubiquitin ligase 
HectH9 is required for the transactivation of multiple Myc target genes (Adhikary et al., 
2005).  Salghetti et al (2001) showed the studies on the activity of a transcription factor 
containing the VP16 transactivating domain (TAD) is regulated through ubiquitination. It 
is known that VP16 TAD signals ubiquitination through the Met30 ubiquitin-ligase and 
that Met30 is also required for the VP16 TAD to activate transcription. The requirement 
for Met30 in transcription can be bypassed by fusion of ubiquitin to the VP16 activator, 
demonstrating that activator ubiquitination is essential for transcriptional function. More 
recently, ubiquitination of Gal4 protein was shown to be essential for its binding to a 
promoter in vivo during transcriptional assays (Archer et al., 2008). Also the 
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ubiquitination of Cdk9 by Skp2 facilitated the formation of the ternary complex between 
P-TEFb, Tat, and transactivation response element (Barboric et al., 2005). These 
interactions are being achieved through the ubiquitin-binding domains (UBDs) present in 
the interacting proteins. The list of proteins with these domains is constantly growing and 
now there are 16 known classes of UBD domains. Ubiquitin-associated (UBA) domains 
are one of the more studied classes of UBDs. Classes 1, 2 and 4 of UBDs also bind to 
mono-ubiquitin, but in all cases with much lower affinity than to polyubiquitin. It is 
proposed that Lys-48-linked polyubiquitin chains may be important for protein 
degradation while Lys-63-linked polyubiquitin chains may play a role in signal 
transduction and transcriptional activation (Hurley et al., 2006). Ubiquitination of Notch 
IC through Lys-63-linked chains may facilitate formation of such a transcriptional 
activation complex. STRAP can possibly help de-ubiquitination of both Lys-48 and Lys-
63 linked polyubiquitin chains and thus may prolong the half life but yet reduce the 
transcriptional activity of ICN3. Future experiments will include elaborate studies to find 
ubiquitination sites on ICN3 and the type of polyubiquitin chains on these residues.  
 
As mentioned earlier STRAP knockout mice had multiple defects including 
angiogenesis, cardiogenesis, somitogenesis, neural tube closure and embryonic turning. 
Though Notch3 mice were viable, fertile, and developed normally, they have some 
defects in vasculogenesis (Domenga et al., 2004; Krebs et al., 2003).  Reports have 
indicated that notch–Dll4 signaling is essential for vascular development in the embryo as 
well as during tumor angiogenesis (Ridgway et al., 2006; Hellstrom et al., 2007; Duarte 
et al., 2004). Notch signaling is also supposed to play a major role during somitogenesis 
(Weinmaster and Kintner, 2003). Interestingly, notch signaling in Drosophila 
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Melanogaster was implicated in tubulogenesis of the tracheal tree during development 
whereas Drosophila homolog of STRAP, named pterodactyl was also shown to be crucial 
for tubulogenesis (Ikeya and Hayashi, 1999; Khokhar et al., 2008). Tubulogenesis and 
branching morphogenesis are vital for the formation of substructure of numerous tissues 
and organs, including the neural tube, kidney, lung, breast, and circulatory system. 
Additional experiments will be needed to know whether notch plays any role in the 
phenotype observed in STRAP knockout mice or the tubelogenesis defect observed in 
pterodactyl knockout in Drosophila. This may be a challenging task considering the very 
diverse range of functions STRAP has been implicated in. 
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CHAPTER V 
 
CONCLUSION AND FUTURE DIRECTIONS 
 
Our current work highlights a fact that for versatile scaffold proteins in the cells, 
it often seems difficult to assess their overall impact on different cellular functions and 
final contribution towards cell behavior. As discussed above, STRAP has been already 
implicated in functions such as TGF-β signaling, PDK1 signaling, ASK1 signaling, 
spliceosomal assembly, mRNA transport, p53 signaling to name a few. In all of these 
cases, STRAP performs its functions through binding with other proteins. Our studies 
have also uncovered two novel roles for STRAP in the cells. 
 
In the first part of the study, we have shown, for the first time, that  deletion of 
STRAP in murine fibroblasts is sufficient to cause MET through upregulation of WT1 
and subsequently E-cadherin.  Re-expression of STRAP in these null cells leads to a loss 
of WT1 and E-cadherin expression, and a reversal from epithelial to the mesenchymal 
morphology. Whether STRAP plays a role in EMT in epithelial cancer cells is not clear 
yet.  
 
In the second part of the study, we show that STRAP interacts with another 
versatile enzyme, GSK3β. We also, for the first time, show that GSK3β binds with ICN3, 
possibly adding it to the list of substrates phosphorylated by GSK3β. Next, we found that 
STRAP also interacts with ICN3. Both STRAP and GSK3β bind with Notch3 through the 
wide ANK domain, containing specialized ankyrin repeats for protein-protein interaction. 
 116 
Although, WD40 domains specialize in recognizing proteins that are post-translationally 
modified, mostly phosphorylated, whether this is the case regarding STRAP and Notch3 
interaction is not known. Interestingly, STRAP expression lead to a decrease in Notch3 
ubiquitination indicating that it may stabilize a specific pool of ICN3 but reporter assays 
indicated that STRAP decreased Notch3-mediated transcriptional activity. These 
contrasting results can be explained by the recent reports indicating role of ubiquitination 
in transcriptional activity of some transcription factors.  
 
Figure 30. STRAP can promote oncogenesis through involvement of multiple 
pathways. 
 
 
STRAP is a relatively small protein of 39 kDa, composed mostly of the WD40 
domain and a short low complexity C-terminal chain.  STRAP, even though not an 
enzyme, can still affect signaling pathways enumerated above though interaction with 
other enzymes in most cases. This reflects the versatility of the WD40 domain. We 
believe that STRAP may interact with additional proteins, transcription factors or 
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enzymes, and affect yet more cellular processes.  Cancer development is a multi-step 
process and cells acquire a cancerous phenotype through the accumulation of multiple 
mutations.  The level of STRAP is found to be altered in different cancers.  The protein 
level is elevated in 60% of colorectal, 78% of lung and 46 % of the breast carcinomas.  
Ectopic expression of STRAP in different cell lines promotes cellular proliferation, 
induces anchorage-independent growth and increases tumorigenicity in in-vitro and in-
vivo experiments. Based on our current understanding, STRAP can influence many 
cellular processes to influence this outcome. This is represented in the schematic of figure 
30. STRAP may be a future possible target for the development of anti-cancer 
therapeutics if small molecule inhibitors can be developed that target specific regions of 
STRAP that will disrupt some specific protein-protein interactions and interfere only 
certain cellular pathways. 
 
Taking the present literature into account, very little is known about STRAP. 
Experiments in a variety of fields will be required to gain a more complete understanding 
of how STRAP affects normal cellular processes/ tumorigenesis and to uncover yet 
unknown functions of STRAP. Here, we plan to do following experiments to further our 
knowledge of functions of STRAP we have uncovered in this work.  
 
1. Effect of STRAP on Notch expression during embryonic development. STRAP 
seems to stabilize Notch3 and some phenotypic features like defective angiogenesis and 
somitogenesis of both STRAP and Notch (1,2 and 3) knockout overlap. We would like to 
generate STRAP knockout mice and obtain tissue samples from the STRAP knockout 
and corresponding wild type mouse embryos. Expression and all Notches will be checked 
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with western blotting. This will give us insight whether some of the features of STRAP 
knockout mice could possibly be attributed to deregulation of Notch signaling. The 
targeting construct will be prepared according to published protocols (Conquet et al., 
1995). The study will be conducted after approval by the Animal Care and Use 
Committee at Vanderbilt University. 
 
2. We will determine the effect of STRAP on Notch3 half life. ICN3 is expressed 
in lung cancer cell lines like HCC2429, H1435, H1418, H1999 etc. (Konishi et al., 2007). 
Since STRAP can possibly stabilize ICN3, we will use the STRAP shRNA lentivirus to 
knock down STRAP in these cells lines and observe any alteration in ICN3 half life. The 
control and STRAP knockdown cells will be incubated for 24 h with poly-L-lysine. The 
cells will be then starved for 3 h in cysteine/methionine-free DMEM (Invitrogen) 
supplemented with 1% L-glutamine and 10% fetal bovine serum and labeled for 2 h by 
the addition of 0.1 mCi/ml Pro-Mix L-[35S] in vitro labeling mix (GE Healthcare). The 
culture medium will be changed to fresh medium containing cold cysteine and 
methionine and chased for the indicated times. At each time point, cells will be harvested 
and lysed. The cell lysates were immunoprecipitated with anti-Notch3 antibody (Cell 
Signaling) and immunocomplexes will be subjected to SDS–PAGE. The separated 
proteins were visualized by autoradiography. A previous report indicates that half life of 
ICN3 is approximately 17 h or 0.7 days (Takahashi et al., 2010). We expect the half life 
of ICN3 to be decreased following decreased STRAP level. 
 
3. We will study the effect of STRAP on transforming ability of Notch1. Stable 
overexpression of ICN1 in HC11 mouse mammary epithelial cells in vitro with the 
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pBabe/Notch1 retrovirus induced puromycin resistant cells which had a transformed 
morphology and were able to form colonies in soft agar (Diévart et al., 1999). The 
ankyrin-repeats are required for this transforming ability of Notch1. STRAP and GSK3β 
bind ICN3 through the same region. We will use the Notch1 overexpressing HC11 cells 
to knock down STRAP using the lentiviral STRAP shRNA (Open Biosystems). For soft 
agar growth assay, clones of vector control and STRAP knockdown Notch1 
overexpressing HC11 cells will be plated in a 35 mm Petri dish at 2x10
4
 cells/ml in 
RPMI-1640 with 10% FCS, EGF and insulin, mixed vol/vol with 0.6% agar (Sigma). 
Colonies will be observed for 3 weeks, and counted under the microscope. Experiments 
will be repeated three times. 
4. MAP1B and Smad3 are validated substrates of GSK3β that have also been 
shown to bind with STRAP. Though the role of STRAP in these interactions has been 
proposed to be quite different from what we have found for ICN3, we would like to see if 
STRAP has any effect on the ubiquitination and stability of these two proteins. Smad3 
being a transcription factor compared to MAP1B which is a structural protein, there is a 
greater possibility of STRAP playing a similar role for Smad3. We will either obtain 
plasmids expressing these proteins and conduct ubiquitination experiments in 293 T cells 
in presence and absence of STRAP as outlined in materials and methods. STRAP 
knockdown clones from various cells lines made in our lab will be used to check Smad3 
and MAP1B expression status and pulse chase analysis will be done to determine any 
alteration in half life of these proteins. Positive results will indicate a more general role of 
STRAP towards GSK3β substrates and negative results would indicate that the role of 
STRAP towards ICN3 deubiquitination is a specific one. 
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